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Japanese encephalitis (JE) virus (JEV) is the main cause of viral encephalitis in South and 
South-East Asia. JEV is a member of the flavivirus Genus (Family Flaviviridae) and it is 
transmitted by mosquitoes. A live attenuated vaccine is used in many endemic countries. 
Dengue virus (DENV) is another flavivirus, closely related to JEV, also transmitted by 
mosquitoes, which is endemic in all tropical and subtropical countries, including India.  
This study aimed to analyse the antibody and T cell responses to the live attenuated JE vaccine 
(LAJV) and their cross-reactivity with the 4 DENV serotypes in adult Indians.  
Participants were vaccinated with the LAJV and peripheral blood mononuclear cell and serum 
samples were collected before and after vaccination. Antibody responses specific to JEV and 
DENV were studied by plaque reduction neutralisation test and ELISA whereas T cell 
responses were measured by interferon γ - ELISpot and intracellular cytokine staining. 
Neutralising antibody (NAb) response to the LAJV was observed in 3 out of 16 volunteers 
(18.75%) with a peak reciprocal geometric mean titre of 20 at 4 weeks after vaccination. Ten 
volunteers (62.5%) were DENV exposed at baseline, as assessed by IgG ELISA. Interestingly, 
original antigenic sin (OAS) was observed in approximately 30% of DENV exposed 
individuals, as shown by the fact that they mounted a NAb response to DENV rather than JEV 
following vaccination. OAS was observed in responders as well as non responders. In addition, 
data suggested DENV NAb at baseline could increase immunogenicity of the vaccine. 
Previous work performed by others on this cohort showed that T cell responses, which peaked 
at 2 weeks following vaccination, were identified in most volunteers by ELISpot. Furthermore, 
T cell responses specific to JEV were detected following vaccination even in volunteers 
without antibody response.  
Five T cell epitopes were identified after vaccination and 4 of them showed cross-reactivity 
with one or more DENV variants. Three of them were also detected before vaccination. T cell 
data indicated that the vaccine was able to induce de novo DENV cross-reactive as well as JEV 
specific T cell responses. Finally, previous cross-reactive DENV responses did not inhibit de 




Japanese encephalitis  
Japanese encephalitis (JE) is a disease caused by Japanese encephalitis virus (JEV). 
Symptomatic infection occurs in 0.1-1% of people infected, with the ratio of 
asymptomatic to symptomatic infection varying with age1,2. JE can present a different 
range of clinical severity going from a fatal meningoencephalomyelitis to milder 
forms like aseptic meningitis or flu like illness3. 
Following infection, after an incubation period of 5-15 days (median of 8.4 days), 
symptoms start with a non-specific febrile illness4. Other clinical features include 
coryza, diarrhoea, rigors, vomiting and headache5. Disease may progress successively 
with altered consciousness, focal neurologic deficits, generalized weakness, 
movement disorders and convulsion. Seizures are more common in children (observed 
in 85% of cases) than adults (reported in roughly 10% of adult JE patients)5. Older 
children and adults may also present abnormal mental behaviour that can potentially 
mislead towards a diagnosis of mental illness6.  
The clinical presentation of a patient with JE includes: a dull, flat mask-like facies, 
unblinking eyes, tremor, hypertonia and rigor. Other extrapyramidal neurological 
features include head nodding, pill rolling movements, lip smacking and facial 
grimacing. Multiple seizures are associated with poorer prognosis7. 
A poliomyelitis like acute flaccid paralysis has been observed in some JE patients8. 
This condition can affect one or more limbs although weakness is more prominent in 
the lower limbs with asymmetrical wasting. Nerve conduction studies and 
electromyographic test demonstrated anterior horn cell damage9.  
JE has a mortality rate of approximately 18%. Around 44% among survivors are left 
with permanent neurological sequelae with important finance and social 
consequences10.  
There is no specific treatment for JE, and management is based on supportive care. 





Outbreaks of encephalitis were recognised in Japan from 1871, with recurrent 
epidemics which occurred during summer. The disease was named “Japanese B 
encephalitis” to distinguish it from von Economo’s encephalitis, known as type A; the 
“B” has since fallen out of use.  
In 1924 a filterable agent from a fatal case of JE was shown to induce encephalitis in 
monkeys. In 1935, the prototype Nakayama strain of JEV was isolated from the brain 
of a fatal case5. 
Virology  
JEV belongs to the genus Flavivirus, family Flaviviridae, which includes 3 other 
genera: Hepacivirus, Pegivirus and Pestivirus. The genus Flavivirus includes over 70 
viruses some of which are transmitted by vectors such as ticks and mosquitoes. The 
genus is further divided in serogroups such as the dengue serogroup which includes 
the 4 dengue virus (DENV) serotypes, the yellow fever serogroup which includes 
yellow fever virus among them, the spondweni group which includes Zika virus 
(ZIKV), and the JE serogroup which includes JEV, West Nile virus (WNV) and 
Murray Valley encephalitis virus (MVEV). The structure and genomic organization is 
conserved among all flaviviruses. The mature virion has a diameter of approximately 
50 nm and contains a single positive strand ribonucleic acid (RNA) genome 
approximately 11kb in size. The 5′ end is capped; the 3′ end lacks a poly-A tail. The 
genome is organized in a long single open reading frame flanked by 5′ and 3′ 
untranslated regions (UTR), from which a single polyprotein is made before being 
subsequently cleaved by host and viral proteases. There are 10 mature viral proteins 
after processing, which include 3 structural (core (capsid), membrane and envelope 
(E)) and 7 non-structural proteins (NS1, NS2a and b, NS3, NS4a and b and NS5)11. 
The 5′ and 3′ non coding regions produce sub-genomic RNAs that are involved in 
interfering with the innate immune response, such as production of type I interferons12.  
The core protein is a small protein of approximately 114 amino acids (AA). The core 
is characterized by basic AA clusters which give it RNA binding properties. Although 
being part of the structure of the virion, core protein was also found in nuclei of the 
cells. Blocking transit of the core protein to the nucleolus decreased viral replication 
in mammal cells and neuroinvasiveness in mice13.  
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The membrane protein is another structural protein, which is produced as pre-
membrane (prM) protein. The main role of the prM is to regulate virus assembly. In 
particular, it works as chaperone helping the E protein in folding correctly14,15. The pr 
fragment has a crucial function during the process of virus maturation (described 
below).  
The last structural protein is the E protein which is a glycosylated protein of 
approximately 500 AA. In the mature virion, E is organized in antiparallel dimers. 
Each virion contains 180 E proteins organized in 90 dimers which are arranged in a 
herringbone fashion with icosahedral T = 3 symmetry (figure 1). The E protein has 3 
domains: EDI, EDII and EDIII. EDI stabilizes the overall orientation of the protein 
and it works like a bridge hinge among the other two domains. EDII is responsible for 
the antiparallel homodimerization and contains the highly conserved hydrophobic 
fusion loop (FL) which mediates virus entry by fusing the E with the membrane of the 
endosome. Finally, EDIII is involved in receptor binding16.  
E is an extremely dynamic protein that goes through structural rearrangements 
triggered by environmental pH. The appearance of the mature virion at neutral pH is 
smooth; however, during the virus entry, in the acidic pH of the endosome the E 
protein  undergoes dramatic rearrangement16. The EDII hinges outward exposing the 
FL that inserts into the host cell membrane of the endosome. This promotes formation 
of 60 E trimers that move to create trimer contacts bending the membranes and 






Figure 1. Schematics and structures of flavivirus particles.  
Representation of immature (left) and mature (right) virions (A). Cryogenic electron 
microscopy structures of immature and mature DENV 1 (B and C). Surface 
representations of the herringbone arrangement of E dimers at the surface of mature 
dengue. EDI is coloured in red, whereas EDII in yellow and EDIII in blue (D). Figure 
reprinted from reference19.   
 
Figure 2. Schematic representation of flavivirus membrane fusion. 
The acidic pH in the endosome promote the formation of E trimers which expose the 
FL. Further structural changes lead to the relocation of EDIII and the formation of a 
trimer in a hairpin-like structure in which the FL and the transmembrane (TM) regions 
are juxtaposed. Subsequently, the E trimers move to create trimer contacts providing 
the energy for membrane fusion. Figure reprinted from reference19.   
 
NS1 is a highly conserved glycosylated protein produced as a dimer, which is 
associated with endoplasmic reticulum (ER) and plasma membrane, and as a hexamer, 
which is secreted20. NS1 has been shown to co-localize with the replication complex 
and be crucial for viral replication20. DENV NS1 has been also implicated in the 
pathogenesis of severe dengue (described below). The JEV serogroup was shown to 
produce another version of NS1, together with the canonical version, called NS1′. 
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NS1′ is produced following a -1 ribosomal frameshift event due to a slippery 
heptanucleotide (YCCUUUU) and an RNA pseudoknot structure towards the 3′ end 
of the NS1 gene20. The final result is an NS1 protein with 52 extra AA that is involved 
in increased neuroinvasiveness21.  
NS2a is a small hydrophobic protein of approximately 231 AA which is associated 
with the ER membrane. It has been shown to strongly bind the viral RNA in the UTR 
region and be involved in viral genome replication in WNV22,23. Studies from WNV 
and DENV described also important roles for NS2a in virus assembly24,25. Finally, it 
has been implicated in interfering with the host immune response. NS2a of JEV is able 
to block the downstream effects of protein kinase R activation by inhibiting eIFα 
phosphorylation26. In WNV, a single mutation (A30P) of NS2a resulted in a mutant 
with attenuated neurovirulence and neuroinvasiveness in vitro and in vivo. The 
mutation induced expression of type I interferons indicating a role for NS2a in 
blocking the host antiviral immune response27.  
NS2b is a small membrane protein of approximately 130 AA. It works as a cofactor 
for NS3 forming a complex that acts as a serine protease. NS2b not only helps NS3 to 
fold correctly but it is also actively part of the substrate binding site of NS3 making 
direct contact with the substrate and therefore participating directly in the catalytic 
activity of NS328. Although, the cytoplasmic portion of NS2b is sufficient to support 
the protease activity of NS3, the transmembrane domains are involved in other 
functions such as virion assembly and viral RNA replication29,30.   
NS3 is the second largest viral protein and consists of two domains which have two 
different functions31. The N terminus has a serine protease activity (in combination 
with NS2b) whereas the C terminus has nucleoside triphosphatase/ RNA helicase/ 
RNA triphosphatase  functions32. This protease is essential for viral replication as it is 
involved in the cleavage of some viral proteins. Aguirre et al. described a role for 
DENV NS2b/NS3 complex in antagonising the antiviral response by cleaving the 
human stimulator of interferon genes (STING) protein33. STING is an adaptor protein 
that is localized in the ER and that, following activation, is able to promote activation 
of the transcription factors interferon-regulatory factor (IRF) 3/7 and NF-κB and 
therefore secretion of type I interferons and pro-inflammatory cytokines34. More 
recently, the motif RxEP present in NS3 protease domain of DENV was described to 
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be involved in ablating innate immune response blocking the translocation of retinoic 
acid-inducible gene I (RIG-I) from the cytosol to mitochondria. A similar motif 
(RLDP) was shown to work in a similar way also for WNV35. 
The helicase domain can recognise double and single strand (ds and ss) RNA and 
unwind it through the energy obtained by the nucleoside-triphosphatase activity36. 
Furthermore, an adenosine triphosphate independent RNA annealing function has also 
been described37. Finally, the RNA triphosphatase activity is considered to be the first 
step for the formation of the cap at the 5′ tail of the viral RNA38. 
NS4a is a small highly hydrophobic protein which works together with NS4b in 
anchoring the viral replication complex to the intracellular membrane. It consists of a 
hydrophilic N terminus which is found in the cytoplasm, a body of 2 hydrophobic 
transmembrane domains and a C terminal domain called 2K (because of its molecular 
weight of 2 kilodalton) that works as a signal sequence for NS4a translocation into the 
ER. Following translocation of NS4a in the ER the 2K fragment is cleaved by 
NS2b/NS339. NS4a has also been implicated in activating the unfolded protein 
response, blocking type I interferons signalling40 and inducing autophagy to prevent 
cell death41, all effects which promote viral replication. 
NS4b is also another hydrophobic protein of 27 kilodalton. DENV NS4b inhibits the 
type I interferons response whereas WNV NS4b is able to induce the unfolded protein 
response and blocks stress granules formation40,42,43. 
NS5 is the biggest and most conserved viral protein with approximately 900 AA. The 
protein consists of two domains: the N terminus which has methyl transferase activity 
and the C terminal which functions as a RNA dependent RNA polymerase (RDRP). 
These two domains are connected by a network of hydrophobic residues which, 
despite not being involved in the catalytic activities of the two domains, are highly 
conserved among all flaviviruses44. Another important function of NS5 is its ability to 
inhibit the host immune response. Despite NS5 is the most conserved protein, different 
mechanisms of immune interference have been described among different 
flaviviruses. JEV NS5 antagonises the host immune response in different ways: 1) it 
is able to block tyrosine phosphorylation of tyrosine kinase 2 and signal transducer 
and activator of transcription (STAT) 1 and the nuclear translocation of STAT1 by 
downregulating calreticulin and increasing the activity of calneurin45,46, 2) it blocks 
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two nuclear transport proteins, KPNA3 and KPNA4, which are involved in the nuclear 
translocation of IRF3 and p65 (a subunit of NF-κB) which regulate the transcription 
of interferon β47. In contrast, WNV NS5 suppresses the expression of the interferon α 
receptor subunit 1 and therefore blocks antiviral signalling of type I interferons48,49.   
DENV and ZIKV NS5 antagonise type I interferons signalling by inducing STAT2 
degradation by the proteasome50–52. 
Flavivirus life cycle 
The first step in the flavivirus infectious cycle is to bind a receptor and enter the cell. 
Several proteins have been identified as putative receptors for the virus entry for 
different flaviviruses. Dendritic-cell-specific ICAM-grabbing non-integrin (DC-
SIGN), the mannose receptor and CD14 were identified as receptors for DENV53–55. 
Heat shock protein 70, glucose-regulated protein 78 and heat shock protein 90β have 
been suggested as putative receptors for JEV56–58. Following virus binding to an entry 
receptor, the virus is internalized through clathrin coated pits and delivered to early 
endosomes which mature into late endosomes59. The low pH in this late endosome 
triggers conformational changes in the E protein which re-assemble as a trimer 
exposing the FL at the tip of the E trimer. The FL interacts with membrane of the 
endosome and EDIII folds back bending the membranes and promoting fusion of the 
viral and endosome membrane (figure 2)60. The capsid is introduced into the cytosol 
of the cell through the resultant pore. The released positive strand RNA is translated 
to produce a single polyprotein which is then cleaved by viral and host proteases. The 
viral genome is subsequently converted into negative sense RNA by the viral NS5 
protein and works as template to generate further copies of the viral genome. Virus 
assembly occurs on the surface of the ER with the viral genome which is packed by 
the capsid protein present on the cytoplasmic side of the ER and the prM and E that 
assemble within the lumen of the ER. Subsequently, the viral particles move towards 
the Golgi and trans-Golgi network (TGN) to finally bud out through by exocytosis. 
The pr fragment, localized on top of the E protein, protects the E from premature 
fusion with the host membrane during the maturation process through the Golgi and 
TGN61. The low pH in the TGN promotes a structural rearrangement of the virion that 
exposes the prM to the cleavage of the host protease furin which cleaves the pr 
fragment from the parent prM protein62. Despite being cut, the pr fragment remains 
associated with the E protein and only detaches from it when the virion buds out of 
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the cell and encounters a neutral pH environment63. At this point, there is a 
conformational change leading the E protein to dimerise and become arranged 
horizontally along the viral surface, protecting the FL underneath EDIII of the adjacent 
E protein. The cleavage of the pr fragment is fundamental for the production of mature 
infectious viral particles. However, this process is not efficient and immature or 
partially mature virus particles are produced during viral replication64,65. These 
immature or partially mature viral particles are relevant especially for DENV as they 
can become infectious through a process of antibody dependent enhancement (ADE) 
(described below). Finally, subviral particles (SVP) are also secreted. These SVP are 
formed as a by-product of virion assembly and contain a lipid membrane and prM-E 










Figure 3. The flavivirus life cycle.  
Virus enter cell by receptor-mediated endocytosis. The acidic pH in the endosome 
triggers the fusion of endosome and virus membrane resulting in the viral genome 
entering the cytoplasm. Following replication of viral RNA and proteins, assembled 
immature viral particles in the ER travel through the TGN and undergo to viral 
maturation process by cleavage of the pr fragment by furin before budding out of the 
cell. Figure reprinted from reference19.   
Epidemiology 
JEV is an arbovirus (arthropod borne virus) and it is transmitted by mosquitoes of 
genus Culex. In particular, Culex tritaeniorhynchus and Culex vishnui are considered 
the main vectors in Asian countries, because of their propensity to breed in rice paddies 
and other dirty stagnant water66. The virus is maintained in the environment through 
an enzootic cycle that involves waterbirds, such as herons and egrets. Pigs play a 
crucial role in transmission to humans by acting as amplifying hosts. Despite the fact 
that pigs do not develop symptoms following JEV infection (although pregnant sows 
can experience abortion), they present prolonged high viraemia so are infectious to 
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feeding mosquitoes. Pigs are kept close enough to human dwellings to facilitate the 
transmission of JEV to humans. In countries where the density of pigs is low, domestic 
birds may contribute to JEV transmission to humans67.  Humans are considered dead-
end hosts as they develop a transient and low viraemia and therefore they are not able 
to transmit the virus to mosquitoes66.  
JEV is considered to be one of the main causes of encephalitis in Asia, with 100,308 
JE cases and 25,125 death estimated in 201568.  
JE is mostly a disease of children with the highest incidence among age 3-6 years. 
Serological surveys in endemic areas showed a high prevalence of neutralising 
antibody (NAb) in adults suggesting immunity in this age group presumably resulting 
from previous infection. However when the virus is introduced into new regions, 
adults are also affected 3.  
Two major patterns of JE are recognised: epidemic and endemic. Epidemics of JE 
occur mainly during the summer in the North Asian countries (23–43° N), whereas in 
South Asian countries (1–13° N) JE is considered endemic6. Furthermore, climatic 
conditions seem to correlate with JE outbreaks with high temperature and low rainfall 
being favourable to the transmission of JEV to humans69.  
Tracking the spread of JEV over time is challenging. Since the first JE epidemics in 
Japan in 1871, the virus has spread to all countries of South and South-East Asia. In 
1995, a serological survey identified the presence of JEV NAb also in the Northern 
region of Australia70. 
Different measures like mass vaccination, use of pesticides, improvement of pig 
rearing practice, implementation of air conditioning inside houses and a reduction of 
mosquito breeding places have been undertaken by different countries to prevent 
transmission of JEV to people. These strategies have been successful; for example 
although the virus still circulates in Japan, South Korea and Taiwan, these countries 
have seen a large reduction, and virtual elimination, of the number of JE cases71. 
Interestingly, following widespread introduction of JE vaccination, Taiwan, Japan and 
South Korea are facing a shift in age population of JE patients with majority of JE 
cases occurring in adults15 16. 
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Based on the full length genome, JEV are classified into 5 genotypes (GI-V). GI and 
III are the most prevalent as they are found in all countries where JEV is endemic. 
More recently, GI has replaced GIII as the dominant genotype74. GII, initially isolated 
in Malaysia, has also been identified in Indonesia, Papa New Guinea, Australia, South 
Korea, Thailand and Japan. GIV has only been isolated from mosquitoes in 
Indonesia75. The first GV strain was isolated from a patient in Malaya. Subsequently, 
GV isolates were obtained from mosquitoes in China and South Korea75. 
 
Figure 4. Geographic distribution of the 5 JEV genotypes.  
A, Indonesia (excluding New Guinea) and Malaysia; B, Australia and New Guinea; 
C, Taiwan (China) and the Philippines; D, Thailand, Cambodia, Vietnam, Laos, and 
Myanmar; E, China, Japan, and South Korea; and F, India, Sri Lanka, and Nepal. 
The numbers in black are the genotypes prevalent before 2000, while grey numbers 
represent the genotypes which emerged after 2000. Figure reprinted from reference75. 
25 
 
The first evidence of JEV in India goes back to the 1950s in Vellore, in the southern 
state of Tamil Nadu76. Although JE was later described in different states, the first 
major JEV outbreak occurred in 1973 in West Bengal (North state of India). In more 
recent years, although there are 24 endemic states for JEV, Uttar Pradesh accounts for 
more than 75% of JE cases77. Following the starting of the JE vaccination campaign 
in 2006 with the live attenuated JE vaccine (LAJV) SA14-14-2, some studies reported 
increasing number of JE cases78. Particularly significant was also the observation of a 
shift of the JE cases from children to adults with a ratio of 1:2.2/3.878–80. However the 
possibility that the increase of JE cases is a reflection of an improved surveillance 
system and diagnosis of JE in India cannot be fully excluded. Finally, the reason of 
the shift of JE cases requires further investigation. In fact, although previous work has 
shown reduced immunogenicity of the SA14-14-2 in Indian adults (described below)81 
a lower vaccination coverage among adults in comparison to children could also 
account for this shift of JE cases82. 
Vaccines 
Prevention of JE can be achieved by vector control or vaccination. As mosquito 
control is not practical to achieve in many areas, efforts have been directly at 
developing JE vaccines. Different vaccine technologies have been applied to develop 
safe and immunogenic JE vaccines.  
Mouse brain derived vaccines 
The first vaccine against JEV was developed by BIKEN (Japan); it was licenced in 
Japan in 1954 and marketed as JE-VAX. This vaccine was also manufactured by the 
Korean Green Cross. JE-VAX was produced by infecting intra-cerebrally 3-4 weeks 
old mice with JEV, the supernatant of mouse brain homogenate containing the virus 
was then treated with formalin and the inactivated virus purified by 
ultracentrifugation. Two different GIII strains were used: Nakayama and Beijing-1. 
The latter strain was originally isolated from the brain of a patient in 1949. The vaccine 
showed 91% efficacy as a monovalent (Nakayama strain only) or bivalent (containing 
Nakayama and Beijing strains) preparation83. In this clinical trial, which was 
conducted in Thailand, a flavivirus endemic country, the vaccine was administrated as 
2 dose schedule. On the contrary, three doses are recommended for travellers84.   
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For many decades JE-VAX was the only vaccine available and it has been used in 
different countries, including China, South Korea, Taiwan and Thailand. Although 
this vaccine has brought down the number of JE cases in many countries, it has several 
drawbacks leading to the development of new and better vaccines. Major 
disadvantages include: the requirement for multiples doses, poor long-term 
immunogenicity requiring booster doses, prohibitive costs for many countries and side 
effects. Local side effects were very common and systemic side effects occurred in 
approximately 10% of vaccinated people. Development of acute disseminated 
encephalomyelitis (ADEM) was the most important risk linked with this vaccine, 
although investigations looking for mouse myelin basic protein in the vaccine 
preparation were negative. In 2005 a child in Japan developed ADEM following JE 
vaccination, in reaction the Japanese Government suspended the use of this vaccine. 
In the same year, the production was interrupted and all the remaining stock expired 
in 2011. However, there is no firm evidence that supported a causal link between JE-
VAX and ADEM85.  
Cell culture derived inactivated vaccines 
This class of vaccines includes 5 different vaccines, which are summarised in table 1. 




Strain Manufacturer Year licenced 
JEBIK Vero Beijing-1 BIKEN 2009 
ENCEVAC Vero Beijing-1 Kaketsuken 2011 
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Two cell culture derived vaccines were developed using the Beijing-1 strain grown on 
Vero cells and then inactivated. The first one was marketed in 2009 by BIKEN 
(JEBIK) and the other one in 2011 by Kaketsuken (ENCEVAC). JEBIK and 
ENCEVAC were both shown to be safe and immunogenic86,87. 
JEVAC is an inactivated Vero cell derived vaccine using the Beijing P-3 strain. In a 
phase III clinical study conducted in children in Thailand, the vaccine, given as 3 dose 
schedule, was safe and highly immunogenic88. 
JENVAC is also a Vero cell derived which makes use of the Indian strain Kolar-
821564XY. A phase 2/3 clinical trial conducted in India showed a seroconversion rate 
(SCR) of 96.9% 8 weeks after vaccination with a 2 dose schedule 81. 
The most used inactivated vaccine is a Vero cell derived vaccine marketed as Ixiario 
which makes use of the attenuated strain SA14-14-2. It is currently approved in 
Europe, the USA, Canada, Australia, New Zealand, Hong Kong, Singapore and Israel. 
The vaccine has been licenced as a 2 dose regimen and it has been proved to be safe 
in children and adults. The SCR in elderly was only 65% at day 70 in comparison to 
>99% observed at day 56 in children89–92. 
Live attenuated vaccines 
There are two live attenuated vaccines: the live attenuated SA14-14-2 vaccine and the 
chimeric JE vaccine. 
The live attenuated SA14-14-2 vaccine was derived from serial passages of the parent 
strain SA14 in primary hamster kidney cells, non-neural tissues of mice and Syrian 
hamsters and suckling mice. Sequencing of the viral genome of the vaccine and the 
parent strain demonstrated about 57-66 nucleotide changes which resulted in 24-31 
AA changes93. Nucleotide changes were found in all the viral genes except prM. 
Although the molecular mechanisms of attenuation are not fully understood, 
particularly important for neurovirulence seems to be the AA substitution G244E94. 
Moreover, the nucleic acid mutation G66A in NS2a was demonstrated to be critical 
for reducing neurovirulence and neuroinvasiveness of the parent strain by ablating the 
production of NS1′ 95. The LAJV SA14-14-2 was initially licenced in China in 1988. 
A two dose vaccine schedule was safe and showed increased immunogenicity over 
one dose, the SCR being around 80-99%96–98. The efficacy of LAJV has been 
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estimated in case control studies, showing that a single dose of the vaccine reduced JE 
cases with an efficacy between 96.2% and 99.3%99,100. Another study however 
demonstrated that the efficacy of a single dose of the vaccine was 80% whereas 
efficacy of a booster dose given at 1 year after vaccination was 97.5%101.  
Some reports from India in adults described the vaccine as being poorly immunogenic. 
Singh et al. observed that seroconversion and seroprotection were 57.69% and 
77.56%, respectively, on day 28 and 39.74% and 60.26%, respectively, on day 5681. 
Another report from India detected a SCR of 73.9% at 28 days after vaccination and 
43.1% after 1 year102. Finally, a retrospective case control study conducted in India 
described a vaccine efficacy of 43.8% based on vaccination card or record103. 
The chimeric JEV vaccine (IMOJEV) is based on the yellow fever virus (YFV) 
vaccine backbone with the prM and E proteins of the SA14-14-2. The vaccine was 
found to be safe in humans104. Initial work investigated the use of the vaccine in YFV 
immune or naïve volunteers105. Although seroconversion was 100% in both groups the 
geometric mean titre (GMT) of NAb was higher in the YFV immune individuals, who 
also had higher viraemia106. In a phase III clinical trial conducted in adults, SCR 
measured with NAb ≥1:10 was 99.1% in comparison to JEVAX, which was 95.1%104. 
Several phase III clinical studies analysed the safety and immunogenicity of IMOJEV 
in children in JEV endemic countries107–109. Furthermore, long term studies 
demonstrated that a booster dose given up to 2 years following primary vaccination 
induced a SCR of 98.2% after 5 years from the booster vaccination107,108.  
The Chimeri-Vax technology has also been used to develop other flavivirus vaccines 
such as the dengue, West Nile and more recently a Zika vaccine. 
Immune responses in viral infection 
Following a viral infection, an innate and adaptive immune response get activated in 
order to control the invader. 
The innate immune response is characterised by a rapid, non-specific, early response 
to a viral infection which helps limit the infection while a more specific adaptive 
immune response take develops. The innate immune system is able to recognise 
viruses as non-self through “sensors” called pattern recognition receptors (PRR). 
These PRR recognise pathogen associated molecular patterns (PAMPs). Some of these 
PAMPs are part of the infectious virus particles whereas others are products of viral 
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replication. PRR involved in viral infections include the toll like receptors (TLR, ten 
have been identified in humans) and the (RIG-I)-like receptors (RLRs). Several TLR 
are involved in the response to viral infections. TLR 3 recognises ds RNA, TLR 4 
interacts with viral glycoproteins such as DENV NS1 triggering a pro-inflammatory 
immune response, TLR 7 and 8 which recognise long ss RNA and TLR 9 which 
responds to unmethylated CpG viral deoxyribonucleic acid (DNA)110. Among the 
RLRs, RIG-I protein detects uncapped 5′ triphosphated ds RNA whereas melanoma 
differentiation-associated protein 5 (MDA-5) can detect long ds RNA110. More 
recently, other PRR have been identified such as DNA-dependent activator of 
interferon-regulatory factors which recognises cytosolic viral DNA111, leucine-rich 
repeat flightless-interacting protein 1 which binds DNA and RNA112 and absent in 
melanoma 2 which promotes inflammasome activation following recognition of viral 
DNA113. Activation of PRR culminates in the production of inflammatory cytokines 
and antiviral type I interferons which help in controlling the infection at an early 
stage110. Another important component of the innate immune response in viral 
infections is the complement system which is a group of proteins that act sequentially 
promoting: a) lysis of enveloped viruses by the formation of pores, b) phagocytosis of 
viral particles through binding to viral protein and promoting opsonisation c) 
stimulation of the inflammatory response to foreign antigens. 
The adaptive immune response consists of antibodies and T cells which are tailored 
for the invading pathogen. Antibodies are produced by plasma cells which 
differentiate from activated B cells. A total of 5 different classes of antibodies have 
been identified: immunoglobulin M (IgM), IgD, IgG, IgA and IgE. IgM and IgD are 
initially expressed on the surface of immature B cells. Following B cell activation by 
recognition of an antigen through the surface immunoglobulins that function as the B 
cell antigen receptor, B cells differentiate into plasma cells and start secreting IgM 
(which are secreted as pentamer), the first antibodies produced. Subsequently, 
interaction between activated B and T cells stimulate the processes of affinity 
maturation and class switching which enables the production of antibodies of 
alternative classes and with higher affinity. IgA (secreted as monomer or dimer) are 
mainly found in mucosal tissues, IgE (secreted as monomers) are mainly involved in 
allergic diseases and defence against parasites. Both IgA and IgE cannot activate the 
complement. Finally, IgG (secreted as monomer) are mainly found in the bloodstream 
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and can pass the placenta providing protection to the fetus as well114. Antibodies 
provide protection against viral infection through 3 different mechanisms: 1) they can 
directly neutralise the virus, 2) they promote viral clearance through antibody 
dependent cell mediated cytotoxicity (ADCC) or opsonisation of viral particles bound 
to antibodies, 3) antibodies bound to viral particles can promote complement 
activation inducing inflammation and lysis of viral particles114. 
T cells recognise antigens through their T cell receptor (TCR). However, T cells can 
only recognise peptide epitopes presented to them by major histocompatibility 
complex (MHC) proteins. T cells fall into functional subsets defined by expression of 
the surface markers CD4 and CD8. CD4 T cells recognise peptides (approximately 
12-25 AA) presented to them by MHC II molecules whereas CD8 T cells recognise 
peptides (8-12 AA) presented to them by MHC I. CD4 and CD8 T cells have different 
roles. The primary role of CD8 T cells is to kill virus infected cells recognised through 
MHC I loaded with viral peptides. CD4 T cells are further subdivided into different 
subsets which are derived from different stimuli provided by antigen presenting cells 
(APC). These subsets include T helper 1 (Th1) cells, which promote the clearance of 
intracellular pathogens by enhancing the killing efficacy of macrophages and 
proliferation of CD8 T cells. Th2 cells are important in fighting extracellular parasites 
such as helminths and allergic diseases by promoting class switching to IgE and 
upregulation of high affinity receptors for IgE on basophiles and mast cells. Th17 cells 
help controlling bacterial and fungal infection by recruitment and activation of 
neutrophils. Other subsets are follicular helper T cells which interact with B cells 
promoting differentiation in antibodies secreting cells and inducing the formation of 
memory B cells and regulatory T (Treg) cells which suppress immune responses and 
inflammation. MHC I and II are expressed on different cell types and bind to their 
target peptide in different intracellular compartments. MHC I molecules are expressed 
on all nucleated cells and bind peptides derived from degradation by the proteasome 
in the ER. MHC II molecules are expressed on APC and bind peptides in the endo-
lysosome where internalized proteins are degraded. However, through a process 
known as cross-presentation, peptides derived from intracellular proteins are able to 





Figure 5. Differences of TCR between CD8+ and CD4+ T cells.  
CD8+ T cells recognize peptides (8-12 AA derived from degradation of an endogenous 
protein) loaded on MHC I molecules. CD4+ T cells recognize peptides (12-25 AA 
derived from an internalized and degraded protein by APC) loaded on MHC II 
molecules. Figure reprinted from reference115. CTLs: cytotoxic T lymphocytes.  
Immune response to JEV and pathogenesis 
The pathogenesis of JEV is not clearly understood and much knowledge is based on 
studies in mice. Following JEV infection in the skin, JEV replicates in local lymph 
nodes, probably, by analogy with dengue virus116, in dendritic cells117. The initial 
innate immune response seems to be critical in determining the subsequent course of 
infection. TLR 3 knockout (KO) mice and mice lacking the type I interferons 
receptor118 are more susceptible to JEV infection. On the other hand, TLR4 KO mice 
were more resistant to virus replication, accompanied by a rapid increase in type I 
interferons119. However, a clinical trial conducted on JE patients showed no 
improvement in the outcome in comparison to placebo control when interferon α was 
administered120. A possible explanation for this failure is that, type I interferons are 
useful in controlling JEV replication only during the initial phase of infection and not 
when JEV has already entered the central nervous system (CNS).  
32 
 
Entry of JEV into the CNS is a critical step in JEV pathogenesis. Although different 
in vitro and in vivo animal studies tried to address how JEV enters the brain, the 
mechanism is still unclear. The distribution of lesions in the human brain at post-
mortem supports a haematogenous route of spread to the CNS121. Replication of JEV 
in human brain endothelial cells (HBEC) was observed in an in vitro model of the 
blood brain barrier (BBB) with an increase in pro-inflammatory cytokines and 
apoptosis of cells122,123. It is interesting to note, however, that another study identified 
viral replication in the brain even before BBB disruption124. Finally, another animal 
study indicated that JEV passes through the BBB by endocytosis and transcytosis 
without active replication in the endothelial cerebral vessels125. Therefore, BBB 
breakdown may be the consequence, rather than the cause, of CNS invasion. Although 
the main target in the CNS is neurons126,127 a pro-inflammatory response is also 
involved in damaging the CNS121,128–130.  
The humoral immune response to JEV has been well characterized in animal models. 
Several studies have shown that NAb are enough to protect from viral challenge. 
Konishi et al. demonstrated that passive transfer of serum from immunized mice was 
able to confer protection to high dose virus challenge131. Similarly, weanling mice 
from immunised mothers, which still have maternal antibodies circulating, were 
protected from challenge with JEV132. Sufficiently neutralising JEV monoclonal 
antibodies (mAbs) can also protect mice from JEV, ruling out any other effect of 
serum133,134. Dilutions of sera with NAb indicated that a minimum NAb titre of plaque 
reduction neutralisation test 50 (PRNT50) of 1:10 is protective135. This has lead to a 
PRNT50 of 1:10 being considered a surrogate marker for protection. As a placebo 
controlled trial to study the efficacy of new vaccines would be unethical, the use of 
this surrogate marker of protection is critical to avoid clinical trials with unpractically 
large sample size136. Additionally, the NAb response to JEV following immunisation 
with IMOJEV was found to neutralise several different genotypes of JEV137. 
Similarly, in humans, among JE patients, higher levels of IgG and IgM were found in 
cerebrospinal fluid as well as plasma of survivors vs non survivors highlighting the 
importance of the antibody response in JEV infection138–140.  
The main target of the NAb is the E protein. Several neutralising mAbs against EDIII 
have been isolated from mice141 . In human, EDIII, although able to elicit NAb, seems 
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less immunodominant with majority of responses identified against EDI and EDII 
which showed a lower level of neutralisation142,143.  
The T cell response to JEV has been less characterized. In animal models, T cells have 
been implicated in protection as well as pathology. JEV was shown to impair the T 
cell priming by dendritic cells by modulating the adaptor molecule myeloid 
differentiation primary response 88 and antigen cross-presentation through MHC I and 
II144–146. Larena et al. demonstrated in a mouse model that both passive transfer of 
CD4 and CD8 T cells individually did not contribute to protection against JEV, though 
improved survival was observed when both T cell subsets were transferred. 
Interestingly, although CD8 T cells alone did not improve survival of challenged mice, 
higher CNS viral load was observed in CD8 depleted mice147. On the contrary, Jain et 
al. demonstrated a critical role for CD8 T cells in clearing virus infected cells through 
their lytic function and stopping the virus to enter CNS148. Similarly, intra cerebral 
adoptive transfer of T cells with cytolytic activity against JEV was shown to rescue 
adult mice from lethal intra cerebral JEV challenge149. Furthermore, a chimeric DENV 
vaccine (prM and E protein) with a backbone based on SA14-14-2, was able to confer 
protection to JEV challenge to mice. As a low NAb titre specific to JEV was detected, 
protection was likely to be due to T cells150. In other studies, CD4 T cells contribute 
to protection by promoting antibody production and isotype switching151–153. 
In humans, CD4 and CD8 T cell epitopes have been described. NS3 was initially 
described as the most immunodominant protein. Kumar et al. observed that the 
frequency as well as the magnitude of T cell responses to an NS3 epitope (AA 193–
324) were lower in JE patients in comparison to healthy JEV exposed individuals154. 
Additionally, lower interferon-γ (IFNγ) production was associated with poor 
outcome155,156. More recently, a CD8 response was shown to be associated with 
asymptomatic JEV infection. These responses were multifunctional and preferentially 
recognised non-structural proteins. On the other hand, CD4 T cells targeting mainly 
the structural proteins dominated the response in JE patients. Furthermore, a 
multifunctional CD4 T cell response in convalescent JE patients was associated with 
more complete recovery from infection. Finally, T cell responses towards the more 
conserved flavivirus epitopes were observed in healthy JE exposed individuals in 
comparison to JE patients who were targeting less cross-reactive epitopes157. These 
data suggest an important role of T cells in controlling the virus. 
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The T cell response to the LAJV has not been fully studied. Recently, work published 
by our group described the T cell response in adult healthy volunteers vaccinated with 
the LAJV in India. T cell responses specific to JEV were described together with cross-
reactive responses. Both CD4 and CD8 T cell responses were observed against all JEV 
proteins158. 
Dengue virus  
Dengue virus (DENV) is another member of Flavivirus that is also transmitted by 
mosquitoes (genus Aedes). There are 4 different DENV serotypes that share 
approximately 70% of their protein sequence and cause a disease with similar clinical 
manifestations to each other. DENV is present in all tropical and subtropical countries, 
including India. All four DENV serotypes are now circulating in Asia, Africa and 
America159. Approximately 400 million infections have been estimated to occur every 
year with roughly 1 in 4 people infected being symptomatic160. Although inapparent 
DENV infection is associated with low viraemia, asymptomatic infections contribute 
to transmission of DENV as they can still transmit the virus to mosquitoes161. 
Symptoms of dengue include severe headache, retro orbital pain, muscle and joint 
pains, nausea, vomiting, swollen glands or rash. According to the WHO guidelines of 
2009 the disease is classified as dengue with or without warning signs and severe 
dengue162. Severe abdominal pain, persistent vomiting, rapid breathing, bleeding 
gums, fatigue, restlessness and vomiting blood are the warning signs that herald the 
development of severe dengue. Established severe dengue is characterised by plasma 
leakage, extra-vascular fluid accumulation, respiratory distress, severe bleeding or 
organ impairment and is a life-threatening condition162. The critical stage is during or 
after the defervescence phase (figure 6) when the patient can rapidly progress towards 
a shock syndrome163. Fortunately, only a small fraction of dengue cases progress 
towards severe dengue. Many sero-epidemiological studies, including some of 
particular significance from Cuba and Thailand, demonstrated the major risk for 
severe dengue is a secondary infection, with an accompanying heterologous antibody 
response164,165.  In addition, age plays an important role in susceptibility with infants 
of 4–9 months of age and children 5–9 years old being at higher risk of developing the 
severe dengue166. Extensive research has been done to explain the pathogenesis of 
dengue highlighting a very complex interplay of viral and host factors that promote 
severe clinical manifestations167. The exact mechanism of severe dengue is still not 
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fully clear though three main hypotheses have been formulated: ADE, original 
antigenic sin (OAS) and antibodies against NS1. 
 
Figure 6. The course of dengue illness.  
The critical phase of the disease which is life-threatening is when fever and viraemia 
are dropping. Shock, bleeding and organ impairment are accompanied by reduction 
in platelet count and increase in haematocrit. Figure reprinted from reference162. 
ADE 
Following a primary infection, antibodies are raised against the infecting serotype. The 
targets of these antibodies include prM, E and NS1 and include both serotype specific  
and cross-reactive antibodies168,169. The primary response is thought to confer lifelong 
protection against the homologous serotype, though rare re-infections with the same 
serotype are described170. However, primary infection is also able to provide 
protection against other serotypes for the first few months171. These data indicate that 
a cross-reactive response which is also cross-protective is possible. On the contrary to 
what observed during primary infection, analysis of the antibody response in 
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secondary heterologous infection reveals that the response is dominated by cross-
reactive antibodies143,172,173. The hypothesis of ADE suggests that some cross-reactive 
antibodies are poorly neutralising and promote infection of Fc receptor bearing cells 
by DENV174,175 (figure 7). The in vitro data indicated that low concentrations of all 
antibodies are able to promote ADE143. More recently, higher incidence of severe 
dengue following a heterologous infection was shown in patients with an anti-DENV 
antibody titre ranging from 1:21 to 1:80176. At the molecular level, this can be possibly 
explained by the work of Chan et al.177. At high concentration of antibodies, large 
immune complexes may form. These immune complexes will interact with FcRIIb 
which is expressed at lower levels than FcRI and IIa and inhibits phagocytosis. ADE 
is thought to contribute to increased severity not only by increasing infectivity of 
DENV on Fc receptor bearing cells but also by promoting suppression of the type I 
interferon response and by increasing the expression of the anti-inflammatory cytokine 
IL-10 in monocytic cell lines178,179. However, increased expression of IL-10 and 
suppression of type I interferons under ADE condition was not observed with primary 
human monocytes180.  
Study of anti-DENV mAbs helped in understanding the humoral immune response to 
DENV and the mechanism of ADE. Antibodies which target prM were found to be 
highly cross-reactive; these antibodies were poorly neutralising even at high 
concentrations but could promote ADE181. Considering the inefficiency of the process 
of cleavage of the pr fragment and the production of mature, partially mature and 
immature viral particles during viral replication, this study also indicated that even 
fully immature viruses (which are not normally infectious) could be rendered 
infectious through ADE by anti-prM antibodies. Another important class of cross-
reactive mAbs described are those able to bind the FL of E protein182. Although the 
FL plays a crucial role during the entry step of infection and it is highly conserved 
among flaviviruses, antibodies that bind it generally have poor neutralising activity. 
On the contrary, they can enhance DENV infection183. Moreover, as observed for anti-
prM antibodies, anti-FL antibodies also had the ability to bind and promote ADE of 
fully immature viral particles. Serotype specific neutralising mAbs have been 
described which bind to more complex quaternary epitopes184. For example, the 
human mAb 5J7 could only strongly neutralise DENV 3 binding to 3 different domains 
of E and each one of them was located on 3 different E proteins185. Another similar 
37 
 
mAb, 2D22, specific to DENV2, was described to bind a quaternary epitope consisting 
of an E dimer and possibly blocking the dimer from rearranging into a trimer186. 
Another two mAbs were described to potently neutralise DENV 1: HM14c10 and 1F4. 
Both these mAbs were able to bind whole virion only187, 188.  
More recently, another class of broadly cross-reactive NAb recognising a novel E 
dimer epitope of the 4 DENV serotypes was described. These antibodies bind the 
interface among the two E proteins that make the dimer, a region that includes the 
FL183, 189. These broadly cross-reactive NAbs were cloned from plasmablasts isolated 
from hospitalised viraemic children during secondary DENV infection.  
Although ADE is thought to contribute to the severity of dengue by increasing 
viraemia, the most important life threatening events, plasma leakage and shock, 
mainly occur when the patient’s fever has broken and the viraemia is dropping or there 
is no circulating virus (figure 6)162. This clearly indicates that ADE alone does not 
fully explain the pathogenesis of dengue. 
 
Figure 7. ADE in DENV infection 
Pre-existing heterotypic antibodies raised during the primary DENV infection may 
bind but poorly neutralise the virus during a secondary heterologous DENV infection. 
These virus-antibody complexes are internalized by Fc receptors bearing cells 
promoting their infection. Figure reprinted from reference190. 
Original antigenic sin 
The phenomenon of OAS was initially described by Dr Thomas Francis Jr. in “On the 
doctrine of original antigenic sin” in 1960191. His hypothesis was based on serological 
data from three different age groups of volunteers who were vaccinated with different 
strains of monovalent influenza vaccine. He observed that before vaccination, in each 
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age group the highest antibody titre against the influenza was against the strain that 
had been circulating during the childhood of that group. The response observed 
following vaccination demonstrated that despite developing an immune response 
towards the strain used for vaccination, the highest antibody response was newly 
detected against the virus strain that was circulating during the childhood for each age 
group192. In addition, animal models of influenza virus demonstrated that OAS can 
reduce the efficiency of vaccination measured by reduced antibody level and increase 
in viral titre after infection193. Interestingly, the degree of OAS induced depended on 
the type of vaccine used with inactivated vaccine inducing the phenomenon only 
minimally in comparison to a DNA vaccine (medium level of OAS) and live 
attenuated vaccine (high level of OAS). Analysis of antibody responses that exhibit 
OAS were however described to be important and partially promote protection194. 
OAS was also observed in different animal models and in humans for other infectious 
diseases such as chlamydia trachomatis and dengue195,196. OAS was later shown to 
exist in T cell responses as well, and impaired the cytotoxic T cell response and viral 
clearance in a mouse model of lymphocytic choriomeningitis virus197.  
The mechanism underlying OAS has not been identified yet although some hypotheses 
have been formulated. One hypothesis relies on competition among naïve and memory 
B cells for epitopes. As memory B cells have a lower activation threshold and higher 
cell frequency outcompete naïve B cells193. Another hypothesis proposed by Ndifon 
suggested a role for Treg in the development of OAS. Treg raised by the original 
antigen get activated during the exposure to the second antigen limiting the amount of 
antigen loaded on APC and therefore reducing the activation of naïve B cells198. Both 
hypothesis are supported by observations that repeated stimulation with the secondary 
antigen or the use of adjuvants to stimulate APC can overcome OAS199. Neutralisation 
of interleukin (IL)-10 (an anti-inflammatory cytokine) can also block OAS although 
in the study Treg were not the source of IL-10200. Although these models require 
experimental validation other questions remain unanswered such as if there is a 
relation between T cells and antibodies with OAS and the consequences of the 
phenomenon of OAS on severity of disease or impairment of vaccine efficacy (and 
not simply antibody levels) in humans.  
In fact, in humans there is lack of evidence of OAS being involved in increased 
severity of a disease or decreasing vaccine efficiency. The only evidence may come 
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from unpublished data from the human papilloma virus (HPV) vaccine (Gardasil 9), 
which is supposed to give protection against 9 serotypes of HPV. Vaccination with 
Gardasil 9 of individuals previously vaccinated with an earlier version of the vaccine 
(Gardasil, which protected only against 4 serotypes) was less efficient in volunteers 
vaccinated with Gardasil 9 alone201. Antibody titre against the 5 HPV serotypes not in 
common with the previous version of the vaccine were observed in 25% in the group 
that received both vaccines vs 69% observed in the volunteers who received Gardasil 
9 alone. However, the clinical significance of this observation is unknown. 
OAS was also initially demonstrated in the antibody response to DENV infection and 
subsequently for T cell responses202. The T cell response to DENV has been 
extensively studied in animal models as well as in human studies. Initial work 
proposed involvement of T cell responses in the pathogenesis of dengue. Although T 
cell epitopes were found in all dengue proteins, NS3 was immunodominant203,204. 
Together with serotype specific T cell responses, cross-reactive T cells were also 
identified with the ability to kill cells pulsed with heterologous dengue peptides205. 
One study demonstrated a higher magnitude of T cell responses but decreased killing 
capacity (measured by the staining CD107a as a marker of degranulation) in dengue 
haemorrhagic fever (DHF) patients203.  The observation of OAS in the T cell response 
to DENV202, together with the description of altered and less vigorous responses with 
decreased cytotoxic activity towards heterologous dengue peptides variants205–207, led 
to speculation of involvement of OAS in the pathogenesis of dengue. During a 
secondary heterologous DENV infection, OAS could promote the proliferation of T 
cells specific to the serotype of the primary infection and a skewed cytokine profile 
that lead to a cytokine storm with subsequent DHF and shock208 (figure 8). However, 
OAS was subsequently observed as a general phenomenon occurring in a dengue 
endemic population and therefore could not explain severe dengue, a rare progression 
of the disease209,210. Additionally, several studies indicated that the T cell response 
may play an important role in protection. Hatch et al. described higher frequencies of 
dengue specific T cells in school children who developed asymptomatic dengue in 
comparison to those who developed clinical manifestation211. Furthermore, animal 
studies corroborated the protective role of CD8 T cells212,213. In humans, HLA 
molecules associated with higher magnitude of response rather than breadth of 
frequency were associated with protection209. An interesting study by Dung et al. 
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demonstrated that in patients with DHF the starting of haemoconcentration and 
thrombocytopenia occurred before the appearance of detectable CD8 T cells specific 
to a dengue epitope214. These data may indicate that the T cell response may contribute 
to both protection and pathology, and is not the only factor contributing to the 
pathogenesis of dengue. 
 
Figure 8.  OAS in T cells in dengue 
During a secondary heterologous DENV infection, T cells raised during a primary 
DENV infection can get activated due to the phenomenon of OAS. These cross-reactive 
T cells out-number T cells specific to the serotype of the secondary infection and may 
promote a suboptimal response which can lead to a cytokine storm. Figure reprinted 
from reference215 
NS1 
The main feature of severe dengue is the development of plasma leakage, which is due 
to increased vascular permeability and can lead to shock. This is a transient state, and 
is believed to be induced by soluble mediators such as cytokines or chemokines. 
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Recently, two independent groups highlighted the importance of NS1 in promoting 
plasma leakage in a mouse model216,217. Inoculation of NS1 alone was sufficient to 
induce vascular permeability and production of pro-inflammatory cytokines and 
chemokines216,217. NS1 was observed to work as a PAMP interacting with TLR4 and 
triggering a strong cytokine production217,218. In vitro studies demonstrated that NS1 
increased endothelial cell permeability directly by disrupting the cell glycocalyx (a 
matrix made of glycoproteins and glycolipids that surrounds the cell membrane) even 
in the absence of cytokines219,220. Additionally, administration of  antibodies against 
NS1 or immunisation with NS1 was able to protect mice from viral challenge 
indicating an important role of NS1 in the pathogenesis of dengue216,221. To a lesser 
extent, protection was also observed when mice were immunised with a NS1 of a 
different serotype of the challenge virus216.  
Another consistent characteristic of severe dengue is thrombocytopenia (reduction of 
platelet count). Reduction in platelets during DENV infection may be mediated 
through multiple mechanisms. DENV can reduce the production of platelets through 
infection of megakaryocytes and suppression of their precursors in the bone 
marrow222–224. Moreover, the humoral response to NS1 was also demonstrated to 
induce antibodies that are able to bind to self-antigens such as platelets, plasminogen 
and endothelial cells225–227. Higher titres of these autoantibodies were observed in 
patients with severe dengue.  
Dengue vaccine  
The only dengue vaccine currently approved in several endemic countries is 
Dengvaxia. Dengvaxia was developed by Sanofi Pasteur and is a tetravalent chimeric 
live attenuated dengue vaccine. The backbone of the vaccine is the yellow fever 
vaccine 17D which expresses the prM and E proteins of each DENV serotype228. A 
phase I and II clinical trials demonstrated the vaccine is safe and can elicit NAb against 
all DENV serotypes229–233. Data from a phase IIb and two phase III clinical trials (one 
conducted in Latin America and one in Asia) demonstrated differences in vaccine 
efficacy against the 4 serotypes with the highest efficacy observed against DENV4 
and the lowest against DENV2. Analysis of the data highlighted also that the vaccine 
was less efficient in volunteers less than 9 years of age234–237. Furthermore, some 
evidence suggested that the vaccine can increase hospitalization in seronegative 




Studying the epidemiology of flaviviruses is critical for public health as highlighted 
by the emergence of flaviviruses in new areas of the globe in the past 20 years. In 1999 
WNV reached the USA for the first time239. More recently, ZIKV reached Yap Island 
in 2007 and from then started spreading reaching French Polynesia in 2013 and Brazil 
in 2015, causing a large outbreak associated with the recognition of more severe 
disease syndromes. Since then, improved surveillance in other countries has 
demonstrated global spread of ZIKV with cases detected in several African and Asian 
countries240.  
This spread of flaviviruses into new areas creates new challenges that must be 
addressed. Flavivirus cross-reactivity is well known and it has important implications 
from a clinical and diagnostic point of view. 
Cross-reactivity among different flaviviruses has been studied previously. Although 
not statistically significant, Hoke et al. described a reduced attack rate and severity of 
dengue fever and DHF in volunteers receiving JEVAX vaccine83. Cross-protection 
was also observed in an animal model, when mice immunised with an inactivated or 
a LAJV were challenged with DENV241. Furthermore, live attenuated flavivirus 
vaccines have increased immunogenicity in people with pre-existing antibodies to a 
different flavivirus242–244. The increased immunogenicity of these vaccines may 
possibly due to an ADE effect that increases viraemia and stimulates a pro-
inflammatory immune response. Cross-reactive ADE from different flavivirus 
immune sera was demonstrated in in vitro studies with contrasting results245,246. In vivo 
effects are also described; recently, Bardina et al. demonstrated in a STAT2 KO mouse 
model an enhanced effect of DENV and WNV immune sera on ZIKV challenge247. In 
humans, Anderson et al. described a higher frequency of symptomatic dengue in 
people with pre-existing NAb to JEV, but no NAb to DENV. However, no difference 
in the presence of NAb against JEV was observed among people who developed 
DHF248.  
Work focusing on flavivirus cross-reactive T cells has also been conducted. Cross-
reactive T cell clones raised from DENV infected donors were demonstrated to react 
and kill target cells pulsed with WNV antigen249. Similarly, JEV specific T cell clones 
could proliferate following WNV antigen stimulation250. Finally, following the recent 
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outbreak of ZIKV, many studies demonstrated important T cell cross-reactivity 
between ZIKV and other flaviviruses251–253. A few studies also focused on the 
implications of cross-reactive T cells in disease. In a mouse model, T cells specific for 
DENV could reduce viraemia in several organs in a ZIKV challenge254. In humans, T 
cell responses in DENV exposed individuals were shown to alter the T cell response 
to ZIKV infection. This influence was observed not only in terms of kinetic of the 
response but also in terms of magnitude, with an earlier and more vigorous T cell 
response observed in DENV exposed individuals. Furthermore, following ZIKV 
infection, a pre-existing DENV T cell response influenced the pattern of recognition 
of ZIKV proteins, with structural proteins targeted in DENV naïve volunteers in 



















Since the use of the live attenuated Japanese encephalitis (JE) vaccine (LAJV) in India 
a shift to relatively increased infections in adult population was observed. Some 
studies have demonstrated a reduced immunogenicity of the LAJV in Indian adults. 
India is endemic to both Japanese encephalitis virus (JEV) and dengue virus (DENV). 
In this project, 17 adult healthy Indian volunteers were vaccinated with a single dose 
of the LAJV. The project aims were: 
 Determine the immunogenicity of the vaccine and related it to previous DENV 
exposure 
 Determine if original antigenic sin occurs following vaccination in DENV 
seropositive participants and analyse it in relation to the immunogenicity of 
the LAJV 
 Identify T cell responses to JEV after vaccination, analyse their cross-
reactivity with DENV variants and determine if they were present before 
vaccination 










































Japanese encephalitis virus (JEV) SA14-14-2, dengue virus (DENV) 1 16007, DENV2 
16681, DENV3 16562 and DENV4 C0036/06 were obtained from Armed Forces 
Research Institute of Medical Sciences (AFRIMS).  
Cell lines 
C6/36 (Aedes Albopictus, larva) and LLC-MK2 (Macaca mulatta, monkey, rhesus, 
kidney) cell lines were obtained from AFRIMS.  
Cell culture media 
All cell culture media are described in the tables below (table 2-10): 
Table 2 Constituents of growth media for LLC-MK2. 
LLC-MK2 growth media 
Reagent Concentration 
M199 NA 







100U/ml and 0.1mg/ml 
NaHCO3 (7.5%) 0.6% 
 











FCS (heat inactivated) 10% 
L-glutamine 2mM 
P/S 300U/ml and 0.3mg/ml 
NaHCO3 (7.5%) 1% 
pH was adjusted to 7.4-7.8 
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Table 5. Constituents of first overlay. 
First overlay 
Reagent Concentration 
Sterile dH2O NA 
HBSS 10x 20% 
FCS (heat inactivated) 10% 
MEM Vitamin solution 
100x 
2% 




P/S 200U/ml and 0.2mg/ml 
NaHCO3 (7.5%) 4% 











Sterile mQ water NA 
HBSS 10x 10% 
P/S 100U/ml and 0.1mg/ml 
NaHCO3 (7.5%) 0.4% 
pH was adjusted to 7.3-74 
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Table 6. Constituents of second overlay. 
Second overlay 
Reagent Concentration 
Sterile dH2O NA 
HBSS 10x 20% 




MEM AA 50x 2% 
pH was adjusted to 6.3 by adding 2M NaOH solution 
 
Table 7. Constituents of R10. 
R10 
Reagent Concentration 
Roswell Park Memorial 
Institute (RPMI) 1640 
NA 
FCS (heat inactivated) 10% 
L-glutamine 2mM 
P/S 100U/ml and 0.1mg/ml 
 










RPMI 1640 NA 




P/S 100U/ml and 0.1mg/ml 




Table 9. Constituents of growth media for C6/36. 
C6/36 Growth media 
Reagent Concentration 
MEM NA 
FCS (heat inactivated) 10% 
L-glutamine 2mM 
P/S 100U/ml and 0.1mg/ml 




Table 10. Constituents of virus infection media. 
Virus infection media 
Reagent Concentration 
RPMI 1640 NA 
FCS (heat inactivated) 5% 
L-glutamine 2mM 
P/S 100U/ml and 0.1mg/ml 
NaHCO3 (7.5%) 0.6% 
 
Antibodies 














CD3 BV510 1:50 UCHT1 BD 
CD4 Percp-Cy5.5 1:50 OKT-4 BD 
CD8 V450 1:200 RPA-T8 BD 
IFNγ FITC 1:50 45-15 Miltenyi Biotec 
TNFα APC 1:50 Mab11 BD 
CD107a PECy7 1:100 H4A3 Ebioscience 
CD19 APC-Cy7 1:50 SJ25C1 BD 
CD20 Percp-Cy5.5 1:50 2H7 BD 
CD27 FITC 1:50 L128 BD 
CD38 PE-Cy7 1:50 HIT2 BD 
 
Primers and probes 
DENV primers and probes were described by Johnson et al.256 similarly JEV primers 











Nucleotide sequence Position Fluorochrome 
JEV Forward GGCTCTTATCACGTTCTTCAAGTTT 239 NA 
JEV Reverse ACTAGTAAGATGTTTCATTGCCACACTCT 344 NA 
JEV Probe ATTAGCCCCGACCAAGGCGCTTT 269 FAM-BHQ1 
DENV1 Forward CAAAAGGAAGTCGTGCAATA 8973 NA 
DENV1 Reverse CTGAGTGAATTCTCTCTACTGAACC 9084 NA 
DENV1 Probe CATGTGGTTGGGAGCACGC 8998 FAM-BHQ1 
DENV2 Forward CAGGTTATGGCACTGTCACGAT 1605 NA 
DENV2 Reverse CCATCTGCAGCAACACCATCTC 1583 NA 
DENV2 Probe CTCTCCGAGAACAGGCCTCGACTTCAA 1008 HEC/BHQ-1 
DENV3 Forward GGACTGGACACACGCACTCA 740 NA 
DENV3 Reverse CATGTCTCTACCTTCTCGACTTGTCT 813 NA 
DENV3 Probe ACCTGGATGTCGGCTGAAGGAGCTTG 762 TR/BHQ-2 
DENV4 Forward TTGTCCTAATGATGCTGGTCG 904 NA 
DENV4 Reverse TCCACCTGAGACTCCTTCCA 992 NA 





Virus growth  
Initial virus titration showed a very low virus titre for all DENV stocks (180, 70, 
2.16x104 and 1.48x103 plaque forming unit/ml (PFU/ml) for respectively DENV1, 2, 
3 and 4) whereas the JEV SA 14-14-2 stock titre was 2.83x107 PFU/ml (virus titres 
were determined by plaque assay described below) (figure 9). Regarding JEV, an 80% 
confluent T25 flask of C6/36 was infected with SA14-14-2 at a multiplicity of 
infection (MOI) of 0.1 in virus infection media with a total volume of 1ml and 
incubated for 1 hour at room temperature on a rocker. The MOI corresponds to the 
number of infectious virus particles added for each cell. At the end of the incubation, 
the volume was brought to 5ml and the flask incubated at 37°C 5% CO2 till 70% 
cytopathic effect (CPE) was observed. To harvest the virus, virus infection media was 
collected and spun down at 4000 revolution per minute (rpm), 4°C for 5 minutes. The 
supernatant was collected and 1ml of heat inactivated FCS, 15% NaHCO3 added to it. 
Finally, the virus suspension was vortexed, aliquoted and stored at -80°C. A similar 
protocol was initially used for the 4 DENV serotypes, however as the virus stocks were 
at lower titre (figure 9), only lower MOI could be achieved: 0.006 MOI for DENV2 
and 4, 0.005 for DENV3 and 0.002 for DENV1. DENV titres measured by plaque 
assay remained low (1.53x103, 2.66x103, 1.7x104 and 1.95x103 PFU/ml respectively 
for DENV1, 2, 3 and 4) (figure 10). A similar experiment was also carried out on LLC-
MK2 for all DENV serotypes obtaining higher DENV titres (9.3x104, 1x105, 8x104 
and 1.2x105 PFU/ml respectively for DENV1, 2, 3 and 4) (figure 10). Finally, all 
viruses were passaged on C6/36 at an MOI of 0.1 before being used for plaque 



































Figure 9. Viral titre of all virus stocks at the beginning of the project (grown on C6/36) 
 
Figure 10. Viral titre of all DENV stocks grown on C6/36 vs LLC-MK2. 
DENV was grown on C6/36 or LLC-MK2 at the following MOI: 0.006 MOI for DENV2 







Plaque assay was used to quantify infectious viral particles. The day before the assay 
was carried out, 1.5x105 cells/well of LLC-MK2 were plated on a 12 well plate 
carefully shaking the plate to make an evenly distributed monolayer and incubated at 
37°C, 5% CO2 overnight. The following day, 10-fold serial dilutions of the virus were 
performed in viral diluent. Cells were washed once with HBSS and 200μl of viral 
diluent added to the cell monolayer together with 100μl of virus serial dilution (each 
dilution was tested in triplicate). A volume of 300μl of viral diluent was used for the 
negative control. Plates were then incubated at room temperature for 1 hour on a 
rocker. Subsequently, the viral inoculum was removed and 1ml of a 1:1 mix of first 
overlay and 2% low melting point (LMP) agarose added. The plate was then incubated 
at 37°C, 5% CO2 for a number of days dependent on the virus tested. JEV and DENV3 
were incubated for 3 days whereas DENV1 and 4 for 5 days and DENV2 for 7 days. 
The days of incubation for each virus were based on a protocol obtained from 
AFRIMS. The day before the last day of incubation 1ml of a 1:1 mix of second 
overlay/4% neutral red and 2% LMP agarose was added. On the last day of incubation, 
plaques were counted and viral titre per ml calculated by applying the following 
formula: average number of plaques from replicate wells x dilution factor from where 
the plaques were counted x 10.  
Initial attempts on setting up PRNT failed to obtain a number of plaques of at least 20 
in the virus control possibly due to an extra incubation step of the virus dilutions at 
37°C for 1 hour required for the assay. An experiment was carried out to study the 
stability of the viruses at 37°C for 1h. Serial viral dilutions (10-fold) of the 5 viruses 
were performed and 2 aliquots generated. One aliquot was incubated at 37°C for 1 
hour before being added to cell monolayer whereas the other one was directly 
inoculated to the cell monolayer. As shown in figure 11, while JEV was stable with a 
3.6% drop, all DENV serotypes showed a reduction of viral titre: DENV2 showed the 
highest percentage drop (90%) followed by DENV1 (75%), DENV4 (33.3%) and 
DENV3 (18.2%) (figure 11). For this reason a modified version of the plaque assay 
was used to determine the virus titre for the stock to be used for PRNT. This modified 
version of the plaque assay included an incubation step of the virus dilutions at 37°C 






Figure 11. Stability of DENV and JEV SA14-14-2 at 37°C for 1 hour. 
Percentage drop of viral titre of the 5 flaviviruses following an incubation period of 1 
hour at 37°C. 
PRNT 
To measure the neutralising antibody titre against all the 5 viruses, PRNT were 
performed. The day before the assay was carried out, LLC-MK2 were plated in a 12-
well plate on growth media at a cell density of 1.5x105 cells/well. Starting from 1:10, 
five 4-fold serial dilutions of heat inactivated serum from volunteers were prepared in 
viral diluent. Virus stock was then diluted to 800 PFU/ml in viral diluent. This virus 
titre allowed to obtain a number of plaques easy to count and with minimal overlap 
between two or more plaques. A 1:1 solution of virus suspension and serum dilutions 
were prepared and incubated at 37°C for 1 hour. A viral control tube was also prepared 
and virus was diluted 1:1 with viral diluent. At the end of the incubation period, cells 
were washed with HBSS and 200μl of viral diluent added to all wells. Subsequently, 
100μl of virus/serum mix was added to the cell monolayer and incubated for 1 hour at 
room temperature on a rocker. Finally, the inoculum was removed and a mix 1:1 of 
first overlay and 2% of LMP agarose added before incubating the cells at 37°C, 5% 
CO2 for a number of days dependent on the virus tested. JEV and DENV3 were 





day before the last day of incubation, a second overlay / 4% neutral red mixed 1:1 with 
2% LMP agarose was added. On the last day of incubation, plaques were counted. 
Each serum dilution and virus control was tested in duplicate.  
Polymerase Chain Reaction  
A single virus was handled at time while performing virus growth to develop virus 
stocks and avoid cross-contamination. Additionally, after a virus stock was prepared a 
real time polymerase chain reaction (PCR) was performed to check for cross-
contamination before using it for PRNT. Viral ribonucleic acid (RNA) was extracted 
by QIAamp Viral RNA Mini Kit (Qiagen) according to manufacturer’s instructions 
and finally eluted in 60μl of AVE buffer.  
DENV RNA was amplified as four-plex using AgPath-ID™ One-Step RT-PCR 
reagents from Invitrogen and the reaction prepared as described in table 13: 
Table 13. PCR reaction mixture for DENV RNA amplification 
Reagent Volume (μl) 
2x buffer 25 
Forward Primers (50μM) 0. 25 for each serotype 
Reverse Primers (50μM) 0.25 for each serotype 
Probes (30nM) 0.3 for each serotype 
Nuclease free water 15.8 
Enzyme 1 
RNA 5 
Total volume 50 
 
The reverse transcription was carried out at 50°C for 10 minutes. Following an enzyme 
activation step performed at 95°C for 5 minutes, amplification consisted of 45 cycles 
of 15 seconds at 95°C (deoxyribonucleic acid (DNA) denaturation) followed by 30 
seconds at 55°C. Fluorescence data were collected at 55°C.   
Regarding JEV amplification, reaction was carried out in two steps: reverse 
transcription and complementary DNA (cDNA) amplification. Reverse transcription 






Table 14. Reaction mixture for JEV RNA reverse transcription. 
Reagent Volume (µl) 
10x reverse transcription buffer 10  
25x dNTPs (50µM in 10mM Tris-HCl) 4  
10x Random primers (50µM in 10mM Tris-HCl) 10  
MuLv reverse transcriptase enzyme (50U/µl) 5  
Nuclease free water  19  
RNase inhibitor (20U/µl)  2  
Extracted RNA 50  
 
The reaction mixture for the cDNA amplification was prepared as described in table 
15. 
Table 15. Reaction mixture for JEV cDNA amplification. 
Reagent Volume (µl) 
2x Taqman Mastermix 12.5 
Forward primer (100µM) 0.125 
Reverse primer (100µM) 0.125 
Probe (15µM) 0.15 
Nuclease free water 4.6 
cDNA 7.5 
 
The reaction consisted of: 2 minutes at 50°C followed by 10 minutes at 94°C to 
activate the enzyme and 40 cycles of 15 seconds at 95°C to denature the DNA and 1 
minute at 60°C for annealing and amplification. The fluorescence data were acquired 
at 60°C. 
Participants 
The process of enrolment of the participants in the study was conducted earlier by Dr 
Lance Turtle. A total of 17 participants were enrolled and vaccinated with the live 
attenuated JEV vaccine SA14-14-2. Vaccine was administered either at the Indian 
Institute of Science or National Institute of Mental Health and Neurosciences 





virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV). One participant 
withdrew from the study after a week therefore it was excluded from this study. 
Majority of subjects were male (76.5%) and mean age at vaccination was 26.6 years 
(table 16). Serum and peripheral blood mononuclear cells (PBMC) were collected 
before vaccination and at week 1, 2, 4, 8, 16 and 26 following vaccination by Dr Lance 
Turtle and cryopreserved.   
Table 16. Age at vaccination of the volunteers 






















PBMC isolation and storage 
PBMC were isolated and stored in liquid nitrogen by Dr Lance Turtle. Blood was 
collected from volunteers and diluted 1:1 with phosphate-buffered saline (PBS). 
Subsequently, diluted blood was slowly added to a 50ml falcon tube filled with 17ml 
of Lymphoprep. Subsequently, blood was centrifuged at 2200 rpm for 22 minutes with 
brake off. PBMCs were aspirated with a sterile Pasteur pipette from the buffy coat. A 
volume of 20ml of R10 was added to the cells and centrifuged at 1800 rpm for 5 
minutes. Supernatant was discarded and cells re-suspended in 10ml of R10 and newly 
centrifuged at 1350 rpm for 3 minutes. Finally, supernatant was discarded and cells re-
suspended in 10ml of R10. PBMC were stored in liquid nitrogen in the following way: 
cells were centrifuged at 1500 rpm for 5 min and re-suspended in ice-cold freezing 
media (heat inactivated FSC, 10% dimethyl sulfoxide (DMSO)) and quickly 
transferred at -80°C in a Mr. Frosty. On the following day, PBMC were transferred in 
the liquid nitrogen.    
PBMC thawing protocol 
PBMCs were quickly removed from the liquid nitrogen and placed at 37°C till ice 
crystals started melting. Subsequently, cells were transferred in pre-warmed R10 
(10ml) and centrifuged at 1500 rpm for 5 minutes. Finally, supernatant was discarded 
and cells re-suspended in 10ml of R10.      
Peptides 
A peptide library covering the whole JEV SA14-14-2 proteome was purchased from 
Mimotopes. The peptides were 15-19 mer with 10 overlapping AA. This length was 
able to cover both CD4 and CD8 T cell responses. The library was organized in 11 
pools and each pool consisted of 6 or 7 mini pools. Pool 1 included the peptides of 
capsid and pre membrane, pool 2 and 3 included peptides of envelope. Among the 
non-structural proteins, pool 4 included peptides of NS1 whereas peptides of NS2a 
and NS2b were combined in pool 5 and those of NS4a and b constituted pool 8. Finally, 
NS3 peptides were split into pool 6 and 7 and those of NS5 in pool 9, 10 and 11 (figure 
12A). All the peptides were dissolved in DMSO and working stock of pools, mini 







Figure 12. Schematic representation of JEV peptide library and example of mini 
pools organisation. 
Organisation of the JEV proteins in pools (A) and example of structure of each pool 
in mini pools and peptides (B). 
The DENV peptides were obtained from BEI resources and a full peptide library 
spanning the whole proteome was available for DENV2 only. Regarding DENV 1, 
DENV 3 and DENV 4 only the peptides of the following proteins were available: E, 
NS1, NS3 and NS5. The peptides were 12 to 18 mer with 11 to 13 overlapping AA 
and they were dissolved in DMSO at 600μg/ml. The peptides represented the 
following DENV strains: strain 16007 as DENV1, New Guinea C as DENV2, 
Philippines H87/1956 as DENV3 and Singapore 8976/1995 as DENV4. 
Expansion of short term T cell lines 
T cell lines were expanded from frozen PBMC. Once thawed, PBMC were rested 
overnight in R10 before proceeding with the stimulation. The following day, 2x106 
PBMC were plated in a 24 well plate in a final volume of 1ml of H10 in presence of a 
pool of peptides (final concentration of 3μg/ml) or mini pool (final concentration of 
5μg/ml) or single peptide (final concentration of 10μg/ml). Subsequently, cells were 





Intracellular cytokines staining 
On the day before the assay, cells were rested in R10 overnight. A total of 2x105 cells 
were plated in a 96-round bottom well plate in 100μl of R10 and stimulated with mini 
pool or single peptide at a final concentration of 5μg/ml for 6 hour at 37°C in presence 
of brefeldin A (10μg/ml) (brefeldin A inhibits protein transport from the endoplasmic 
reticulum to the Golgi therefore blocking the secretion of cytokines). DMSO at a 
concentration of 0.8% was used as negative control and phorbol 12-myristate 13-
acetate (PMA) (25ng/ml) and Ionomycin (500μg/ml) as positive controls. If expression 
of CD107a was also assessed, 1μl of anti-CD107a monoclonal antibody (details in 
table 11) was also added. After the incubation, cells were first stained with live dead 
(Near IR, BD) (diluted 1:1000 in PBS) for 20 minutes in the dark at room temperature 
and subsequently fixed and permeabilised with 100μl of BD cytofix/cytoperm for 20 
minutes in the dark at room temperature. Cells were stained with monoclonal 
antibodies against CD3, CD4, CD8, IFNγ and TNFα (details in table 11) in a volume 
of 50μl of perm wash (1x, BD) for 30 minutes at 2-8°C and finally re-suspended in 
200μl of PBS. Cells were acquired on FACS ARIA III or FACS Verse together with 
compensation controls and data analysed using FlowJo with the gating strategy shown 
in figure 13. Forward and side scatters were used to gate on lymphocytes (figure 13A) 
whereas forward scatter area vs height was used to exclude duplets and gate single 
cells only (figure 13B). Live/dead staining was performed to discriminate live from 
dead cells. Live/dead staining consisted of a fluorescent amino reactive molecule that 
is not able to penetrate the cell membrane. Therefore, dead cells which do not have an 
intact cell membrane allowed the amino reactive molecule to stain also internal amino 
groups resulting in a brighter staining. Live T cells were gated based on the T cell co-
receptor multimeric protein complex CD3 (figure 13C). T cells were subsequently 
differentiated into CD4 and CD8 subsets (figure 13D) and responding cells were gated 
by analysing the secretion of IFNγ and/or TNFα (figure 13E). Finally, the ability of the 
T cells to kill their target cells was analysed by using the degranulation marker CD107a 
(figure 13F). CD107a is the lysosomal-associated membrane glycoprotein 1 (LAMP-
1) which is present in the pre-formed lytic granules, containing perforin and 
granzymes, which are secreted during the killing process by T cells. This process 
exposes CD107a to the cell membrane and allows the binding of a labelled monoclonal 
antibody specific to CD107a (which is added during the assay set up after the addition 






Figure 13. Representative gating strategy used to analyse responding T cells. 
Lymphocytes were gated using forward and side scatters (A). Forward scatter area vs 
height was used to gate on single cells (B). Live T cells were gated as live/deadlow 
CD3+ cells (C) and differentiated into CD4 and CD8 subsets (D). Responding T cells 
were gated by analysing the secretion of IFNγ and TNFα in any combination (E). 
Finally, degranulating T cells were gated as CD107a+ cells (F).  
Plasmablast staining 
Thawed PBMC were counted and 5x105 cells were plated in a 96 round bottom well 
plate in R10. Subsequently, cells were incubated for 20 minutes in the dark at room 
temperature with live/dead (Far red, BD) (diluted 1:1000 in PBS) and stained with 
labelled antibodies (CD19, CD20, CD38, CD27, details in table 11) for 30 minutes at 
2-8°C in a volume of 50μl of PBS. Finally, antibodies were washed away and cells re-
suspended in PBS before acquiring them on FACS Verse together with compensation 
controls. Data analysis was performed using FlowJo with the gating strategy described 
in figure 14. Forward and side scatter were used to gate on lymphocytes (figure 14A) 





cells only (figure 14B). Live/dead staining was performed to discriminate live from 
dead cells (figure 14C). The B cell markers CD19 and CD20 were used to discriminate 
plasmablasts with this cell population being CD19+CD20- (figure 14D). Finally, 
plasmablasts were gated as CD27highCD38high cells (figure 14E). CD27 is a marker for 
memory B cells whereas CD38 is a marker of cellular activation and proliferation.   
 
Figure 14. Representative gating strategy used to identify plasmablast cells.  
Lymphocytes were gated using forward and side scatters (A). Forward scatter area vs 
height was used to gate on single cells (B). Live cells were gated as live/deadlow cell 
population (C) and plasmablasts gated as CD19+CD20- (D) and CD27highCD38high (E) 
cells. 
ELISpot 
All the reagents used to perform IFNγ-ELISpot were purchased from Mabtech. The 
day before the assay was carried out, 96 well polyvinylidene difluoride membrane 
plates were coated with 100μl/well of anti-IFNγ monoclonal antibody (clone 1-D1K) 
at a final concentration of 10μg/ml in PBS. Subsequently, the plate was wrapped in 
parafilm and incubated at 2-8°C overnight. The following day, the plate was washed 





incubated at 37°C, 5% CO2 for at least 2 hours. Overnight rested PBMC were washed 
with R10 and added to a cell density of 2x105 cells/well in a final volume of 50μl of 
R10. Peptide mini pools or single peptides were diluted at a concentration of 6μg/ml 
in R10 and 50μl added to wells to achieve a final concentration of 3μg/ml. A volume 
of 50μl of R10 with 1% DMSO was added to the negative control well whereas 50μl 
of R10 with Concanavalin A (Sigma) at a concentration of 10μg/ml was added to the 
positive control wells. Plate was finally incubated at 37°C, 5% CO2 overnight. The 
following day, the plate was washed 7 times with 200μl of PBS Tween 20 (0.05%) 
(PBST) and 50μl of the biotinylated anti-IFNγ antibody (clone 7-B6-1) at a final 
concentration of 0.5μg/ml (diluted in PBS/0.5% bovine serum albumin (BSA)) was 
added to each well and the plate incubated at room temperature at dark for 1 hour. 
Subsequently, the plate was washed 4 times with PBST before adding 50μl of 
streptavidin conjugated alkaline phosphatase diluted 1:1000 in PBS/0.5% BSA. Plate 
was incubated for 1 hour at dark at room temperature. Finally, the plate was washed 4 
times with PBST and 50μl of filtered 5-bromo-4-chloro-3-indolyl-phosphate/nitro 
blue tetrazolium (BCIP/NBT) added and incubated for 5-15 minutes till spots 
developed and reaction was stopped by washing the plate with distilled water 4 times. 
The plate was dried out before reading the spots on an AID ELISpot reader. A response 
was considered positive if the spot count was at least three times the negative control.   
ELISA 
IgM and IgG against JEV and DENV were detected by using 4 kits (table 17) according 













Table 17. ELISA kits used for detection of IgG and IgM specific to JEV and DENV 
Virus Antibody type Kit Manufacturer 
JEV 
IgM 
JEV IgM Capture 
ELISA 
National Institute 
of Virology (Pune) 
IgG 















Briefly, for JEV IgM, heat inactivated sera were diluted 1:100 and added to the 96-
well ELISA plate and incubated for 1 hour at 37°C. At the end of the incubation, 
samples were washed off and JEV antigen added and incubated for 1 hour at 37°C. 
Subsequently, an anti-JEV monoclonal antibody was added and incubated for 1 hour 
followed by 1 hour of incubation in presence of avid-horseradish peroxidase (HRP). 
Colour was developed by adding 3,3′,5,5′-tetramethylbenzidine (TMB) substrate and 
stop solution added after 10 minutes. Finally, optical density (OD) was measured at 
450nm. Sample readout was based on manufacturer’s instructions. A sample was 
deemed positive if the OD value was higher that one of the negative control by a factor 
of 3. If the OD value of the sample was exceeding that one of the negative control by 
a factor between 2 and 3-fold, the sample was considered equivocal whereas if it was 
less than 2-fold, the sample was considered negative. 
For JEV IgG, heat inactivated sera were diluted 1:300 and added to the 96-well ELISA 
plate pre-coated with JEV recombinant antigen and normal cell antigen. After having 
washed away the samples, anti-IgG HRP conjugated antibodies were added and colour 
developed by adding TMB followed by adding stopping solution. OD values were read 
at 450nm. Sample readout was based on manufacturer’s instructions. An immune 





between 2 and 5 was considered equivocal whereas a value above 5 was considered 
positive. 
For DENV IgM, heat inactivated sera were diluted 1:100 and added on anti-human 
IgM pre-coated 96 well ELISA plates. After 1 hour of incubation, antigen-monoclonal 
antibody conjugated with HRP was added and incubated for another hour. At the end 
of the incubation, colour was developed by adding TMB and stopped by adding 
stopping solution. OD values were read at 450nm with a reference filter at 600-650nm. 
Sample readout and OD ratio was calculated according to manufacturer’s instructions. 
An OD ratio below 0.9 was deemed as negative, whereas and OD ratio between 0.9 
and 1.1 was considered equivocal. Finally, an OD ratio above 1.1 was considered 
positive. 
Regarding DENV IgG, heat inactivated sera were diluted 1:100 and added to 96 well 
ELISA plate and incubated for 30 minutes at 37°C. At the end of the incubation period, 
anti-human IgG HRP conjugated were added and colour developed by adding TMB 
followed by adding stopping solution. OD values were read at 450nm with a reference 
filter at 600-650nm. Sample readout and OD ratio was calculated according to 
manufacturer’s instructions. An OD ratio below 0.9 was deemed as negative, whereas 
and OD ratio between 0.9 and 1.1 was considered equivocal. Finally, an OD ratio 
above 1.1 was considered positive. 
Statistic 
PRNT70 values were calculated by probit analysis using SPSS software. A PRNT70 
value of 1:10 was considered positive. If a volunteer had PRNT70 above 1:10 at 
baseline, a 4-fold increase was considered as response to the vaccine. Statistical 
analysis were performed with GraphPad Prism. All unpaired non-parametric data were 
analysed by Mann Whitney U test whereas the paired non-parametric data were 
analysed by Wilcoxon test. Finally, all correlations were performed with non-
parametric data and analysed by Spearman test. P values <0.05 were considered to be 
statistically significant. 
Ethics 
The study was conducted according to the principles of the Declaration of Helsinki. 
Written consent was obtained from all the participants and the protocol approved by 





of Tropical Medicine (ref. 10.59) and NIMHANS (NIMH/DO/ETHICS/SUB-
























































The live attenuated SA14-14-2 Japanese encephalitis (JE) virus (JEV) vaccine (LAJV) 
is currently the main JE vaccine used in endemic countries. Several studies have 
already described the safety, immunogenicity and efficiency of this vaccine in children 
in endemic countries98, 258.   
The gold standard method used to measure neutralising antibodies (NAb) against 
flaviviruses is by plaque reduction; a 50% plaque reduction neutralisation titre 
(PRNT50) of at least 1:10 is considered protective.  
This study was conducted in a country where the 4 serotypes of dengue viruses 
(DENV) and JEV are co-endemic259. As we were interested in analysing the specificity 
of the NAb against all DENV serotypes as well as JEV, a more stringent PRNT cut-
off was used. Therefore we used the 70% plaque reduction titre: the serum dilution 
able to give a reduction of the number of plaques by 70% in comparison to virus 
control (PRNT70). Furthermore, antibodies that better neutralise DENV grown on 
C6/36 rather than dendritic cell derived virions have been described183. This difference 
is due to a diverse efficiency in cutting the pr fragment during the maturation process 
resulting in different prM content in DENV particles grown on insect vs dendritic cells 
with the latter showing a lower percentage of prM. PRNT50 includes the neutralisation 
effect of these antibodies and therefore can overestimate the neutralisation potential of 
the antibody titre. However, virus derived from C6/36 cells is thought to represent 
better the infecting virus derived from a mosquito260. As the viruses used in this study 
were grown on C6/36, use of PRNT70 helped to exclude this overestimation. 
A titre of at least 1:10 of PRNT70 measured following vaccination was used to 
discriminate responders and non responders. As previously, if a volunteer was 
seropositive at baseline (PRNT70 of 1:10 or above), a 4-fold increase in the NAb titre 
following vaccination was used to define seroconversion81,158.  
JEV and DENV co-circulate in many different countries in South and South East-
Asia259. Cross-reactivity between these two flaviviruses raises important diagnostic 
and clinical concerns. Due to the importance of pre-existing anti-DENV antibodies in 
severe dengue, the role of antibodies in dengue and more generally in flaviviruses has 
been studied extensively. Flavivirus cross-reactive antibodies bind to conserved 





these cross-reactive antibodies is the fusion loop (FL): a portion of the domain 2 of the 
envelope protein which contains a hydrophobic region that is important for the fusion 
of the virus with the endosomal membrane following a drop in pH. This step is critical 
for the viral capsid and genome to enter the cytoplasm of the host cell. Despite the 
important role of this region in the infectious cycle, antibodies against the FL are 
poorly neutralising. In addition, anti-FL antibodies promote antibody dependent 
enhancement (ADE) increasing infectivity of DENV to Fc receptor bearing cells261,182. 
More recently, anti-FL antibodies raised following DENV infection were also 
described in a mechanism of Zika virus (ZIKV) enhancement in vitro and in vivo262.  
Another well studied target of antibodies is prM. During the process of viral replication 
inside the host cells, the prM structural protein is cleaved by furin making a mature 
infectious viral particle. However, this process is inefficient resulting in the production 
of a mixture of mature, immature and partially mature viral particles. Antibodies 
targeting the prM can promote ADE allowing immature non-infectious virus particles 
to infect Fc receptors bearing cells. 
As a large component of the antibody responses to flaviviruses consists of non/poorly 
neutralising antibodies263, NAb are preferentially used to determine seroconversion in 
vaccine studies.     
The antibody response during a secondary heterologous DENV infection is also 
characterized by the phenomenon of original antigenic sin (OAS)195,264. This 
phenomenon was also described for the T cell response in DENV infection202. The 
clinical effect of OAS in the antibody response is still not clear. There is some 
evidence, however, of OAS, or at least cross-reactivity in the T cell response being 
protective195,209,210,264.  
The work presented in this chapter will focus on the specificity of the antibody 
response raised following JE vaccination with particular reference to the phenomenon 
of OAS. Previous studies have shown low immunogenicity of LAJV in India81,102. 
Vaccination with LAJV was used as a model to study the specificity of the antibody 
response in a secondary flavivirus infection. This model was used to test the hypothesis 
that participants with previous exposure to DENV will show OAS by mounting a 
higher NAb response against DENV than JEV following LAJV vaccination possibly 





was the possibility to study the samples obtained just before the vaccine administration 
and follow the response at different time points after vaccination.  
LAJV was administrated to a total of 17 volunteers although one of them withdrew 
after a week and was excluded for this study. PRNT were measured in serum samples 
obtained at week 0, 4 and 8. In order to measure binding antibody (as opposed to 
neutralisation), IgM and IgG ELISAs for JEV and DENV were also performed for 
samples collected at week 0 and week 4. Finally, plasmablast populations were 
measured at week 0, 1 and 2 if cells were available. 
Although the serum samples collected before vaccination were available from all the 
participants, one participant was missing a sample at the week 4 time point, and 2 
subjects had sample missing at the week 8 time point. All subjects had at least one post 
vaccine serum sample available. 
Results 
NAb response specific to JEV following JE vaccination  
One participant (015c3k1) was JEV seropositive by PRNT70 before vaccination 
(reciprocal NAb titre of 13). Four weeks after vaccination only 3 participants (18.75%) 
seroconverted (seroconversion was determined by a titre of at least 1:10 of PRNT70 
measured following vaccination or at least a 4-fold increase in participants seropositive 
at baseline) whereas the only participant JEV seropositive at baseline showed an 
increase of NAb titre of 3.9 fold, therefore this participant was considered as non-
responder (table 18).  
Eight weeks after vaccination, JEV PRNT70 of 1:10 or above were observed in only 2 
participants, including the participant seropositive at week 0. However, it is important 
to note that 2 out of 3 participants who seroconverted at week 4 no longer showed 














Week 0 Week 4 Week 8 
Seroprotecteda 




005c3k1 0 10 12 Yes Yes 
001c1k1 0 37 9 Yes Yes 
023c1k1 2 22 9 Yes Yes 
015c3k1 13 51 18 Yes No 
023c3k1 0 2 3 No No 
020c1k1 0 0 3 No No 
008c3k1 0 0 0 No No 
019c3k1 0 0 0 No No 
007c1k1 0 0 NA No No 
017c1k1 0 0 0 No No 
022c3k1 1 0 0 No No 
018c1k1 0 0 0 No No 
012c3k1 2 5 6 No No 
020c3k1 0 0 0 No No 
004c1k1 0 0 NA No No 
010c3k1 3 NA 7 No No 
a Seroprotection is defined as any participant with PRNT70 ≥1:10.  
b Seroconversion (vaccine responder) is defined as PRNT70 ≥1:10 measured following 
vaccination or at least a 4-fold increase in titre in participants seropositive at baseline (PRNT70 
1:10 or above). 
Overall, 3 out of 16 participants (18.75%) responded to the vaccine with a peak 
response observed at week 4 and a reciprocal geometric mean titre (GMT) of 20. Eight 
weeks after vaccination, a drop of the JEV titre was observed with a reciprocal GMT 
of 11 and PRNT70 ≥1:10 detected in only 2 participants (figure 15). 
These data demonstrated that LAJV was not very immunogenic for NAb response in 
the population studied. Additionally, in terms of magnitude of the antibody response, 
















Figure 15. NAb to JEV following LAJV administration. 
Reciprocal JEV PRNT70 measured at week 0, 4 and 8 in responders vs non responders 
following LAJV vaccination. Lines and error bars indicate the geometric mean and 
the 95% confidence interval. One participant who had a reciprocal PRNT70 titre of 51 
at week 4 was included in the non responders group as it was seropositive at baseline 
and showed a 3.9-fold change increase following vaccination.  
NAb response to DENV following JE vaccination 
To test the hypothesis that vaccination with the LAJV could have increased the titre of 
cross-reactive NAb against one or more DENV serotypes, PRNT70 for each DENV 
serotype were performed at baseline and 4 and 8 weeks after vaccination. Overall, NAb 
against all DENV serotypes were detected (table 19).  
Table 19. Prevalence of NAb against the 4 DENV serotypes 
DENV 
serotype 
Participants with DENV 
NAb at baseline 
Participants with DENV 
NAb at any time point 
DENV1 10 (62.5%) 11 (68.75%) 
DENV2 11 (68.75%) 11 (68.75%) 
DENV3 8 (50%) 10 (62.5%) 






NAb against DENV1 was detected in a total of 11 participants (at any time point). 
Among them, one participant (019c3k1) who had PRNT70 <10 at week 0 seroconverted 
at week 4 (1:31) and week 8 (1:19). The reciprocal GMT of NAb against DENV1 at 
baseline in the 11 participants who were DENV1 seropositive (at any time point) was 
110.7. No increase in NAb titre against DENV1 among the DENV1 seropositive (at 
any time point) participants was observed following JEV vaccination with a reciprocal 
GMT of 103.1 at week 4 and 103.5 at week 8 (figure 16). One volunteer (022c3k1) 
had a reciprocal NAb titre of 10 at baseline that dropped to below 10 at week 4 and 8.  
 
Figure 16. NAb against DENV1 following LAJV administration. 
Reciprocal of DENV1 NAb titre measured by PRNT70 in DENV1 seropositives (at any 
time point) (n=11) participants measured at week 0, 4 and 8 following LAJV 









Table 20. Reciprocal NAb titre against DENV1 measured by PRNT70 
DENV1 NAb titre 
Participant ID Week 0 Week 4 Week 8 
Vaccine 
Responder 
005c3k1 205 402 306 Yes 
001c1k1 58 99 106 Yes 
023c1k1 919 928 939 Yes 
015c3k1 570 636 926 No 
023c3k1 0 0 0 No 
020c1k1 81 104 115 No 
008c3k1 230 120 190 No 
019c3k1 6 31 19 No 
007c1k1 176 333 NA No 
017c1k1 0 0 0 No 
022c3k1 10 0 0 No 
018c1k1 0 0 0 No 
012c3k1 39 49 30 No 
020c3k1 0 0 0 No 
004c1k1 0 0 NA No 
010c3k1 552 NA 484 No 
 
DENV2 
Anti-DENV2 NAb were observed in 11 participants with a reciprocal GMT of 284.2, 
291.6 and 324.2 at week 0, 4 and 8 respectively. Therefore, no increase in NAb titre 
was observed following JE vaccination among the DENV2 seropositive participants 






Figure 17. NAb against DENV2 following LAJV administration 
Reciprocal of DENV2 NAb titre measured by PRNT70 in DENV2 seropositives (at any 
time point) (n=11) participants measured at week 0, 4 and 8 following LAJV 















Table 21. Reciprocal NAb titre against DENV2 measured by PRNT70 
DENV2 NAb titre 
Participant ID Week 0 Week 4 Week 8 
Vaccine 
Responder 
005c3k1 420 386 404 Yes 
001c1k1 717 1254 1207 Yes 
023c1k1 1405 1244 1820 Yes 
015c3k1 657 747 1138 No 
023c3k1 8 4 2 No 
020c1k1 66 78 78 No 
008c3k1 285 200 159 No 
019c3k1 380 212 142 No 
007c1k1 55 522 NA No 
017c1k1 0 0 0 No 
022c3k1 1 0 2 No 
018c1k1 50 18 40 No 
012c3k1 428 313 367 No 
020c3k1 0 0 0 No 
004c1k1 0 0 NA No 
010c3k1 410 NA 494 No 
 
DENV3 
A total of 10 participants showed NAb against DENV3 during the course of the study 
with a reciprocal GMT of 32.7 at baseline. Two of them (019c3k1 and 007c1k1) were 
seronegative at week 0 and showed an increase of NAb following LAJV vaccination 
only at week 4. The reciprocal GMT calculated among these 10 participants against 
DENV3 was 57.2 at week 4 and 57 at week 8. Overall, a median of 1.1 and 1.3 fold 
increase of the NAb titre over baseline was measured for week 4 and week 8 






Figure 18. NAb against DENV3 following LAJV administration. 
Reciprocal of DENV3 NAb titre measured by PRNT70 in DENV3 seropositives (at any 
time point) (n=10) participants measured at week 0, 4 and 8 following LAJV 















Table 22. Reciprocal NAb titre against DENV3 measured by PRNT70. 
DENV3 NAb titre 
Participant ID Week 0 Week 4 Week 8 
Vaccine 
Responder 
005c3k1 49 55 53 Yes 
001c1k1 39 35 85 Yes 
023c1k1 343 189 179 Yes 
015c3k1 675 478 505 No 
023c3k1 0 0 0 No 
020c1k1 13 15 13 No 
008c3k1 25 55 39 No 
019c3k1 1 20 7 No 
007c1k1 4 66 NA No 
017c1k1 0 0 1 No 
022c3k1 0 0 0 No 
018c1k1 0 0 0 No 
012c3k1 13 35 23 No 
020c3k1 4 0 0 No 
004c1k1 0 0 NA No 
010c3k1 160 NA 202 No 
 
DENV 4 
NAb against DENV4 were less prevalent, being detected (at any time point) in only 6 
participants. The reciprocal GMT of NAb against DENV4 at baseline in DENV4 
seropositives (at any time point) was 79. Although not statistically significant an 
increase in GMT was observed at week 4 and 8 with a reciprocal GMT of respectively 
99.2 and 159.3 (figure 19). As observed for DENV1 and DENV3, one participant 
(005c3k1) who was seronegative at baseline showed NAb against DENV4 at week 4 
(1:37) and week 8 (1:54). Overall, the data regarding the NAb titre against DENV4 






Finally, four participants were seronegative at baseline for all the 4 DENV serotypes 
and remained seronegative throughout the whole study period. 
 
Figure 19. NAb against DENV4 foloowing LAJV administration. 
Reciprocal of DENV4 NAb titre measured by PRNT70 in DENV4 seropositives (at any 
time point) (n=6) participants measured at week 0, 4 and 8 following LAJV 














Table 23. Reciprocal NAb titre against DENV4 measured by PRNT70 
DENV 4 NAb titre 
Participant ID Week 0 Week 4 Week 8 
Vaccine 
Responder 
005c3k1 9 37 54 Yes 
001c1k1 23 92 68 Yes 
023c1k1 636 617 444 Yes 
015c3k1 103 123 228 No 
023c3k1 0 0 0 No 
020c1k1 2 8 5 No 
008c3k1 0 0 0 No 
019c3k1 0 0 0 No 
007c1k1 45 13 NA No 
017c1k1 0 0 0 No 
022c3k1 2 0 0 No 
018c1k1 0 0 2 No 
012c3k1 438 309 286 No 
020c3k1 0 0 0 No 
004c1k1 0 0 NA No 
010c3k1 1 NA 3 No 
 
Effect of DENV NAb on immunogenicity of LAJV 
Previously, Chan et al. demonstrated that pre-existing NAb against inactivated JE 
vaccine increased the immunogenicity of yellow fever vaccination243. To test the 
hypothesis that previous DENV exposure may increase the immunogenicity of the 
LAJV, the NAb response to LAJV was analysed by DENV serostatus at baseline. 
Interestingly, for all DENV serotypes, the GMT in those who responded to JE vaccine 
was higher than those who did not. However, this difference was statistically 
significant (p value <0.05, Mann-Whitney test) only for DENV2 (figure 20A, table 24 
and 25). To exclude the possibility that is effect may be driven by DENV seronegative 
participants who are only present in the group which did not respond to LAJV, they 





observed in the responder group (p value <0.05, Mann-Whitney test) (figure 20B, table 
24 and 25). 
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Figure 20. DENV NAb at baseline in responders vs non responders to LAJV. 
Reciprocal PRNT70 against DENV1-4 measured in responders vs non responders to 
the LAJV (A) and responders vs non responders DENV seropositive at baseline to the 
LAJV (B) at week 0. Asterisks indicate a p value <0.05 analysed with Mann-Whitney 





Although the number of participants was small, this analysis suggested that DENV 
serostatus at baseline has the potential to influence the JE vaccine immunogenicity. 
The fact that statistical significance was observed only against DENV2 may be due to 
the higher prevalence and NAb titre of DENV2 in Karnataka state265.  
Following LAJV, no change in NAb titre against DENV1, DENV2 and DENV3 was 
seen in the responder group. On the contrary, NAb titres against DENV4 showed a 
median increase of 3.9 fold at week 4 and 2.9 fold at week 8. No overall change was 
observed in the participants who did not respond to the vaccine although a 2.5 fold 
increase was observed for DENV3 when DENV seronegative individuals were 
excluded from the analysis (figure 21 and table 24 and 24). Although these data 
confirmed that some individuals developed DENV NAb following LAJV, the small 
sample size precluded meaningful statistical testing.  
In summary, these data provided no evidence that previous DENV infection interferes 
with JE vaccination. On the contrary, higher DENV NAb at baseline may play a role 








Figure 21. Fold change DENV NAb titre following LAJV vaccination. 
Fold change NAb titre against DENV1-4 at week 4 (A and B) and 8 (C and D) among 
responders vs non responders (A and C) and responders vs non responders DENV 
seropositive (B and D) following LAJV. Lines indicate median values. 






JEV DENV1 DENV2 DENV3 DENV4 
Responders 
Week 0 <10 223 751 87 52 
Week 4 21 334 844 72 129 
Week 8 10 312 961 94 118 
Non 
responders 
Week 0 <10 15 33 <10 <10 
Week 4 <10 10 24 <10 <10 








Table 25. Summary table of GMT of all viruses at all time points stratified per 





JEV DENV1 DENV2 DENV3 DENV4 
Responders 
Week 0 <10 223 751 87 52 
Week 4 21 334 844 72 129 





Week 0 <10 86 198 24 128 
Week 4 <10 63 186 52 79 





Week 0 <10 <10 <10 <10 <10 
Week 4 <10 <10 <10 <10 <10 
Week 8 <10 <10 <10 <10 <10 
   
ELISA IgG and IgM  
PRNT allows the detection of NAb only. Most of the participants showed no change 
in NAb titres after LAJV. We hypothesised that one reason for this may be that non-
neutralising antibody is made following vaccination. In order to test this hypothesis, 
ELISA for IgG and IgM specific to JEV and DENV on the serum samples collected at 
week 0 and 4 were performed.  
Following a viral infection the first class of antibodies produced are IgM. Detection of 
JEV specific IgM may therefore identify participants who did not develop NAb but 
responded to the LAJV by making non-neutralising antibody of IgM subclass. One 
participant (007c1k1) was JEV IgM positive before vaccination and at week 4. As this 
participant was dengue IgM negative, cross-reactivity with dengue IgM is less likely. 
This result could indicate a possible recent asymptomatic infection with wild type JEV, 
or a false positive. This participant was an adult resident in urban Bangalore in good 
health, making recent JEV infection very unlikely. Overall, five participants tested 





When analysing the total level of JEV IgM a statistically significant higher OD ratio 
was observed following LAJV vaccination (p value <0.05, Wilcoxon test) (figure 22). 
 
Figure 22. Total JEV IgM following LAJV administration. 
JEV IgM OD ratio before and after vaccination in all participants. Asterisks indicate 














Table 26. OD ratio IgM JEV specific measured at baseline and 4 weeks after 
vaccination. 
JEV IgM ELISA 
Participant 
ID 










005c3k1 2.03814 Equivocal 3.9661 Positive Yes 
001c1k1 2.47881 Equivocal 4.24153 Positive Yes 
023c1k1 2.69492 Equivocal 3.25424 Positive Yes 
015c3k1 2.182203 Equivocal 2.754237 Equivocal No 
023c3k1 0.97458 Negative 1.9661 Negative No 
020c1k1 2.22458 Equivocal 2.25424 Equivocal No 
008c3k1 1.923729 Negative 1.639831 Negative No 
019c3k1 2.05932 Equivocal 1.80932 Negative No 
007c1k1 3 Positive 4.19915 Positive No 
017c1k1 1.39831 Negative 7.72881 Positive No 
022c3k1 1.89831 Negative 2.31356 Equivocal No 
018c1k1 1.41525 Negative 2.70339 Equivocal No 
012c3k1 1.41525 Negative 1.54237 Negative No 
020c3k1 0.83051 Negative 1.79237 Negative No 
004c1k1 1.98305 Negative 2.83898 Equivocal No 
010c3k1 1.99576 Negative NA NA No 
 
When stratifying according to the response to the vaccine by PRNT70, a higher OD 
ratio was observed at week 4 in both groups. However, this increase was statistically 
significant only for the participants who did not make NAb (p value <0.05, measured 
by Wilcoxon test) (Figure 23). This result remained significant even after excluding 
the participant with the OD ratio of 7.7 at week 4. Overall, these data may indicate that 
most participants responded to the vaccine by producing antibodies that did not 





showed clear evidence of seroconversion, with a change in OD ratio of 1.4 pre vaccine 
to 7.7 afterwards. 
  
Figure 23. JEV IgM among responders and non responders (by NAb) to the 
LAJV. 
OD ratio of IgM specific to JEV in vaccine responders and non responders to the LAJV 
by PRNT70 measured at baseline and 4 weeks after vaccination. Asterisks indicate p 
value <0.05 analysed by Wilcoxon test. Error bars represent median and interquartile 
range. 
As some participants showed increases in DENV specific NAb after LAJV to exclude 
the possibility that this was due to an asymptomatic DENV infection, DENV specific 
IgM were measured by ELISA at week 0 and 4. DENV IgM was negative at both time 
points in all the participants. These data indicated that a DENV infection of the 










Table 27. OD ratio IgM DENV specific measured at baseline and 4 weeks after 
vaccination. 
DENV IgM ELISA 
Participant 
ID 









005c3k1 0.29346 Negative 0.28368 Negative Yes 
001c1k1 0.22079 Negative 0.19145 Negative Yes 
023c1k1 0.40525 Negative 0.37311 Negative Yes 
015c3k1 0.19704 Negative 0.17887 Negative No 
023c3k1 0.05031 Negative 0.02655 Negative No 
020c1k1 0.600894 Negative 0.463946 Negative No 
008c3k1 0.11878 Negative 0.1062 Negative No 
019c3k1 0.15931 Negative 0.20263 Negative No 
007c1k1 0.12856 Negative 0.19843 Negative No 
017c1k1 0.11319 Negative 0.1607 Negative No 
022c3k1 0.05729 Negative 0.07965 Negative No 
018c1k1 0.91951 Equivocal 0.92091 Equivocal No 
012c3k1 0.15092 Negative 0.17188 Negative No 
020c3k1 0.09782 Negative 0.07686 Negative No 
004c1k1 0.173281 Negative 0.017188 Negative No 
010c3k1 0.12437 Negative NA NA No 
 
Following the initial IgM response, B cells undergo a class switching and affinity 
maturation processes which result in an antibody response dominated by IgG. 
Therefore, JEV specific IgG levels were measured at baseline and week 4 following 
LAJV administration. Detection of JEV specific IgG may identify participants who 
did not develop NAb but responded to the LAJV by making non-neutralising antibody 
of IgG subclass. Two participants had a positive result in the JEV IgG ELISA before 
vaccination. After LAJV administration, JEV IgG ELISA OD ratios did not increase; 
4 weeks after vaccination only 1 participant was positive to JEV IgG (figure 24 and 






Figure 24. Total JEV IgG following LAJV administration. 
JEV IgG OD ratio before and after vaccination in all participants. Error bars 
represent the median and interquartile range. 
Subdividing by response to LAJV by PRNT70, there was no further evidence of an IgG 
response to LAJV in either those who made neutralising antibody responses or those 
who did not. Higher JEV IgG was observed among responders vs non responders (by 
PRNT70) which was statistically significant at baseline only (p<0.05, Mann-Whitney 
U test) (figure 25). The observation that higher OD ratios were observed at baseline in 
the participants who mounted NAb responses following LAJV, and that the 2 
volunteers JEV IgG positive at baseline were JEV seronegative and DENV 
seropositive at baseline by PRNT70, suggested the possibility of cross-reactivity 






Figure 25. JEV IgG among responders and non responders (by NAb) to the 
LAJV. 
OD ratio of IgG specific to JEV in vaccine responders and non responders to the LAJV 
by PRNT70 measured at baseline and 4 weeks after vaccination. Asterisks indicate p 

















Table 28. OD ratio of JEV specific IgG detected at baseline and 4 weeks after 
vaccination 
JEV IgG ELISA 
Participant 
ID 









005c3k1 6.23214 Positive 10 Positive Yes 
001c1k1 2.27941 Equivocal 3.37879 Equivocal Yes 
023c1k1 5.40741 Positive 1.67797 Negative Yes 
015c3k1 1.78689 Negative 2.68254 Equivocal No 
023c3k1 0.64894 Negative 0.96825 Negative No 
020c1k1 1.34545 Negative 2.46 Equivocal No 
008c3k1 1.05455 Negative 1.21311 Negative No 
019c3k1 1.58065 Negative 2.77419 Equivocal No 
007c1k1 3.0137 Equivocal 2.7973 Equivocal No 
017c1k1 0.90476 Negative 0.60185 Negative No 
022c3k1 1.05085 Negative 0.89231 Negative No 
018c1k1 1.04839 Negative 0.69318 Negative No 
012c3k1 2.2716 Equivocal 2.62121 Equivocal No 
020c3k1 0.98214 Negative 1.05172 Negative No 
004c1k1 0.94286 Negative 0.98551 Negative No 
010c3k1 2.01389 Equivocal NA NA No 
 
To test the hypothesis that the JEV IgG assay may detect cross-reactive antibodies, 
JEV IgG data were analysed according to DENV serological status. The JEV IgG OD 
ratio was significantly lower in DENV seronegative compared with seropositive 
participants (by PRNT70) at baseline (Mann-Whitney test, p<0.05) and 4 weeks after 
vaccination (Mann-Whitney test, p<0.05) (figure 26). Furthermore, only a modest 
correlation was found among JEV PRNT70 and JEV IgG ELISA for the data at week 
4 (Spearman, r=0.5288, p<0.05) (figure 27). On the contrary, no correlation was found 
for the data at week 0 (Spearman, r=0.2171, p=0.4172) (figure 27). Finally, a better 





serotype, compared with JEV PRNT70 (figure 28). Altogether these data strongly 
suggest that this JEV IgG assay detects antibodies that are cross-reactive with DENV.  
 
Figure 26. JEV IgG following LAJV in participants DENV seropositive vs 
seronegative. 
JEV IgG OD ratio in DENV seronegative and DENV seropositive (by PRNT70) 
participants at week 0 and 4 following vaccination. Asterisks indicate p value <0.05 
by Mann-Whitney U test. Error bars represent the median and interquartile range.   
 
Figure 27. Correlation among JEV IgG and PRNT70 







Figure 28. Correlation among JEV IgG and DENV PRNT70. 
Correlation among DENV1-4 PRNT70 and OD ratio of JEV IgG at week 0 (A) and 4 
(B) (Spearman test). 
DENV IgG was detected in 10 participants (62.5%) at baseline. All of them also had 
DENV NAb detected at least against one serotype. Only 2 participants had DENV 
NAb detected but they were DENV IgG negative (018c1k1 was DENV 2 positive by 
NAb at both time point, week 0 and week 4, and 022c3k1 was DENV1 positive at 





significant variation of the OD ratio. Moreover, samples collected at week 4 for the 
subjects who were DENV IgG negative at baseline remained negative (table 29). 
Table 29. OD ratio IgG DENV specific measured at baseline and 4 weeks after 
vaccination. 
DENV IgG ELISA 
Volunteer 
ID 












005c3k1 4.71233 Positive 4.53425 Positive Yes 
001c1k1 4.33521 Positive 4.34811 Positive Yes 
023c1k1 4.80902 Positive 4.50443 Positive Yes 
015c3k1 4.40935 Positive 4.28606 Positive No 
023c3k1 0.02337 Negative 0.02579 Negative No 
020c1k1 2.871072 Positive 2.99194 Positive No 
008c3k1 2.93392 Positive 3.02176 Positive No 
019c3k1 1.70105 Positive 2.59226 Positive No 
007c1k1 4.15471 Positive 4.1805 Positive No 
017c1k1 0.07977 Negative 0.06285 Negative No 
022c3k1 0.06044 Negative 0.04432 Negative No 
018c1k1 0.11039 Negative 0.07897 Negative No 
012c3k1 3.99436 Positive 3.96696 Positive No 
020c3k1 0.02256 Negative 0.0145 Negative No 
004c1k1 0.070105 Negative 0.11442 Negative No 
010c3k1 3.66156 Positive NA NA No 
 
Overall, a strong and significant correlation among PRNT70 values (the highest titre 
among the 4 DENV serotypes was used for this analysis) and DENV IgG OD ratio at 
week 0 (r=0.8609, p<0.05) and 4 (r=0.8793, p<0.05) was observed (figure 29A) 
(Spearman test). When correlating DENV IgG with DENV PRNT70 for each DENV 
serotype, although good correlation was observed for all DENV serotypes, a stronger 





the highest NAb titres  (figure 29 B and C). As shown above, and in previous work, 
pre-existing flavivirus antibody exposure may increase the immunogenicity of a 
secondary flavivirus vaccine243. To confirm the observations described above, DENV 
IgG levels were compared between those who mounted NAb responses to LAJV 
(defined by PRNT70) and those who did not. Those participants who responded to JE 
vaccination had significantly higher OD ratios for DENV IgG at baseline (figure 30) 
(p value <0.05, Mann Whitney U test). To confirm that this difference was not due to 
the fact that no DENV seronegative participants made NAb responses to LAJV, a 
similar analysis was conducted excluding all the participants who were DENV 
seronegative. Interestingly, a significant difference could still be observed with higher 
DENV IgG OD ratios at baseline in those who responded (figure 30) (p value <0.05 
by Mann Whitney U test). These data are in agreement with the NAb data and indicate 
that a higher titre of DENV IgG may help the antibody response to LAJV. In addition, 
considering the cross-reactivity detected by the JEV IgG ELISA, the higher OD ratio 
of DENV IgG in those who responded is consistent with the hypothesis that higher OD 
ratio of JEV IgG at baseline is simply a reflection of the cross-reactivity of the assay 
with DENV. If this were the case DENV and JEV IgG should be strongly correlated. 
Interestingly, testing this showed a very strong correlation between JEV and DENV 
IgG OD ratio at both week 0 (Spearman test, r=0.91, p<0.001) and 4 (Spearman test, 
r=0.80, p<0.001) (figure 31) further confirming cross-reactivity with DENV detected 











































Figure 29. Correlation between DENV IgG and PRNT70 
Correlation among DENV IgG OD ratio and PRNT70 at week 0 and 4 using the higher 






Figure 30. DENV IgG and response to the LAJV (by NAb). 
OD ratio of IgG specific to DENV grouped according to the responsiveness to JEV 
vaccination (by PRNT70) (A and C for week 0 and 4 respectively) and excluding the 
DENV seronegative participants (B and D for week 0 and 4 respectively). Asterisks 
indicate p value <0.05 analysed by Mann-Whitney test. Error bars represent median 






Figure 31. Correlation among DENV AND JEV IgG. 
Correlation between OD ratio of DENV IgG and JEV IgG at both week 0 and 4 
(Spearman test).  
Individual antibody responses to LAJV – evidence of original antigenic 
sin 
The small size of this study limited the ability to draw conclusions as to the reasons 
why immunogenicity (at least in terms of NAb response) was poor in this population. 
However, one hypothesis we wished to investigate was whether DENV exposure 
interfered with the response to LAJV through OAS, indicated by a participant with 
pre-existing DENV exposure mounting higher a DENV NAb than JEV NAb response 
to LAJV. As described above, DENV exposure appeared to have the opposite effect, 
that is DENV2 NAb levels at baseline were markedly higher in responders, achieving 
statistical significance even with this small sample size. There was no evidence of 
OAS in the cohort overall, although DENV4 NAb did show a trend to rising after 
LAJV, but during the course of the work it became apparent that there was marked 
variation in the responses of different participants. Although the small numbers 
impeded the ability to find any association of OAS with vaccine non-response, if 
observed, we could conclude that an OAS interaction exists between DENV and JEV 
in this cohort. 
In order to test the hypothesis that OAS occurs after LAJV, responses were analysed 





against any DENV serotype than against JEV following LAJV. In addition, at least a 
4-fold increase in DENV NAb titre should be observed following vaccination.    
Among those who made NAb responses, 001c1k1 showed greatest fold change of 
PRNT70 JEV titre (7.48 fold increase). This participant was seronegative at baseline 
for JEV and the NAb response peaked at week 4 with a PRNT70 of 37 (figure 32A). 
However, at week 8, JEV PRNT70 dropped below 10. JEV ELISA IgM and IgG OD 
ratios also showed a small increase (1.5 fold, figure 32B). Additionally, at week 0, this 
participant was seropositive for all DENV serotypes with the highest NAb titre 
obtained against DENV2 (717) followed by the other serotypes which had similar NAb 
titre (58, 39 and 23 for DENV1, DENV3 and DENV4 respectively). An increase in 
PRNT70 against all DENV serotypes was observed following vaccination. In 
particular, a rise in NAb titre was detected at week 4 for DENV1, DENV2 and DENV4 
and for all DENV serotypes at week 8. The increase in NAb titre against DENV4 with 
a 3.9 fold change at week 4 and 2.9 at week 8.  
In addition, to further investigate the antibody response, plasmablasts (newly 
responding B cells) were measured in blood after vaccination. This cell population has 
been described to increase in blood after vaccination266. In this volunteer, a 1.8 fold 
increase in the plasmablast population measured by flow cytometry was observed at 























































Figure 32. Summary of antibody response to LAJV in 001c1k1.  
Summary of antibody response to LAJV in 001c1k1 by PRNT70 (JEV and DENV1-4 at 
week 0, 4 and 8, reciprocal titre) (A), IgG and IgM ELISA (JEV and DENV at week 0 
and 4, OD ratio) (B) and plasmablast response (at week 0, 1 and 2, percentage of 
CD19+CD20-CD38 highCD27high cells) (C).   
The second highest NAb response to the vaccine was observed in 023c1k1 with a 4.4 
fold increase at week 4 (figure 33A). JEV ELISA IgM did not change between week 
0 and week 4, whereas IgG at week 0 which was strongly positive became negative at 
week 4 (figure 33B). Regarding DENV specific NAb, 023c1k1 was positive at baseline 
against all serotypes with reciprocal PRNT70 of 919, 1405, 343 and 636 for DENV1, 
DENV2, DENV3 and DENV4 respectively. DENV specific IgG ELISA was also 
positive at baseline. No relevant increase of DENV NAb titre was observed for this 
participant following vaccination. Plasmablasts staining showed an expansion of 2.1 





   
Figure 33. Summary of antibody response to LAJV in 023c1k1. 
Summary of antibody response to LAJV in 023c1k1 by PRNT70 (JEV and DENV1-4 at 
week 0, 4 and 8, reciprocal titre) (A), IgG and IgM ELISA (JEV and DENV at week 0 
and 4, OD ratio) (B) and plasmablast response (at week 0 and 1, percentage of 
CD19+CD20-CD38 highCD27high cells) (C).  
The final participant who seroconverted following vaccination was 005c3k1. Despite 
a strongly positive JEV IgG ELISA before vaccination, no JEV neutralisation was 
observed at baseline by PRNT70. Four weeks after vaccination, JEV NAb titre rose to 
10 and peaked at 8 weeks after vaccination with a PRNT70 value of 12 (figure 34A). 
A rise of IgM and IgG was observed by JEV ELISA with a 1.9 and 1.6 fold rise 
respectively of the OD ratio between week 0 and week 4. This participant was DENV 
seropositive at baseline, with NAb detected against DENV1, 2 and 3. Interestingly, 
following JEV vaccination, a rise in NAb titre against DENV1 and DENV4 was 
observed, though the DENV IgG ELISA titre did not change. DENV1 NAb titre rose 





higher for DENV4 with an increase of 4 and 6 fold measured at week 4 and 8 
respectively. The higher response observed against DENV4 than to JEV (which was 
the antigenic stimulus) demonstrates OAS in this participant. No concurrent DENV 
infection was observed during the period of observation as confirmed by the negative 
results of ELISA IgM DENV specific at week 0 and 4. Insufficient samples were 
available from this participant for plasmablast measurement. 
 
Figure 34. Summary of antibody response to LAJV in 005c3k1. 
Summary of antibody response to LAJV in 005c3k1 by PRNT70 (JEV and DENV1-4 at 
week 0, 4 and 8) (A), IgG and IgM ELISA (JEV and DENV at week 0 and 4) (B). 
A further 9 volunteers had DENV NAb at baseline, but did not mount NAb response 
to the vaccine. Of these, two volunteers, 007c1k1 and 019c3k1 showed increase in 
DENV NAb following LAJV.  
Only the time points week 0 and week 4 were available for 007c1k1. Interestingly, this 





seen (1.4 fold increase) following vaccination. JEV specific IgG was equivocal at both 
time points and did not change after vaccination. DENV specific IgG and PRNT70 at 
week 0 indicated this subject was DENV seropositive at baseline, with NAb against 
DENV1, 2 and 4 (figure 35 A). A large increase in DENV2 NAb titre was observed 
following JE vaccination, DENV1 NAb also increased and there was seroconversion 
to DENV3, again indicating OAS (figure 35A). It is interesting to note also the 
magnitude of the response with a 1.89, 9.4 and 13.3 fold increase of the antibody titre 
respectively for DENV1, DENV2 and DENV3. The response following the 
vaccination was accompanied by plasmablast expansion that peaked at week 1 with a 
3.6 fold increase (figure 35C). 
 
Figure 35. Summary of antibody response to LAJV in 007c1k1. 
Summary of antibody response to LAJV in 007c1k1 by PRNT70 (JEV and DENV1-4 at 
week 0 and 4) (A), IgG and IgM ELISA (JEV and DENV at week 0 and 4) (B) and 
plasmablast response (at week 0, 1 and 2, percentage of CD19+CD20-CD38 





For participant 019c3k1, there was no change in JEV IgM following vaccination, 
though there was a small rise (1.7 fold) in JEV IgG ELISA OD ratio at week 4. DENV 
specific NAb at baseline was observed only against serotype 2. Interestingly, this 
participant seroconverted for DENV1 and 3. PRNT70 values for DENV 1 and 3 were 
<10 before JE vaccination; 4 weeks after vaccination reciprocal NAb titres for DENV 
1 and 3 were 31 and 20 respectively, indicating OAS, or at least a cross-reactive 
response which neutralised some DENV serotypes better than JEV. Plasmablast 
















Figure 36. Summary of antibody response to LAJV in 019c3k1.  
Summary of antibody response to LAJV in 019c3k1 by PRNT70 (JEV and DENV1-4 at 
week 0, 4 and 8) (A), IgG and IgM ELISA (JEV and DENV at week 0 and 4) (B) and 






The remaining 7 participants who had DENV NAb at baseline, did not respond to 
LAJV with detectable NAb by PRNT70 and did not show any significant change in 
DENV NAb titres after vaccination. Of these participants, 012c3k1 showed a >2 fold 
increase in the plasmablast population at 14 days post LAJV (figure 37).  
 
Figure 37. Summary of antibody response to LAJV in 008c3k1, 012c3k1, 015c3k1, 
010c3k1, 022c3k1, 020c1k1 and 018c1k1.  
Summary of antibody response to LAJV in 008c3k1, 012c3k1, 015c3k1, 010c3k1, 
022c3k1, 020c1k1 and 018c1k1 by PRNT70 (fold change of NAb titre for JEV and 
DENV1-4 at week 0, 4 and 8) (A), IgG and IgM ELISA (JEV and DENV at week 0 and 
4) (B) and plasmablast response (at baseline and day 7, 12 and 14, percentage of 
CD19+CD20-CD38 highCD27high cells) (C). 
Finally, 4 participants had no DENV antibodies at baseline and did not make detectable 





had IgM ELISA OD ratios that at least doubled 4 weeks after vaccination, one of whom 
also showed an increase in the plasmablast population after vaccination (figure 38). 
 
Figure 38. Summary of antibody response to LAJV in 023c3k1, 020c3k1, 004c1k1 
and 017c1k1. 
Summary of antibody response to LAJV in 023c3k1, 020c3k1, 004c1k1 and 017c1k1 
by IgG and IgM ELISA (JEV and DENV at week 0 and 4) (A) and plasmablast response 
(at week 0, 1 and 2, percentage of CD19+CD20-CD38 highCD27high cells) (B). 
Overall, OAS was observed in 3 participants and for all DENV serotypes. In particular, 
OAS was detected in 2 participants for DENV3, in 1 participant for DENV1, DENV 
2 and DENV4. Interestingly, OAS was never observed for the DENV serotype with 
the highest NAb titre for each participant. 
Although only 3 participants developed OAS, OAS occurred among participants who 
developed NAb and who did not (figure 39 and table 30). Approximately 30% of the 
participants who were DENV seropositive (by IgG or PRNTs) showed OAS (table 31 
and 32). As the study was small and only three participants responded to the JE vaccine 
(by NAb), analysis of the difference of the JEV neutralising GMT among responders 
who developed OAS versus those who did not was not possible. However, it is possible 
to conclude that DENV NAb influences the response to LAJV, and that LAJV 






Figure 39. Schematic representation of the overall NAb response and OAS 
observed in this study. 
Table 30. Prevalence of participants who developed OAS among responders and 
non-responders (by NAb) to LAJV administration 
 Sin Non sin Total 
Responder 1 (33.3%) 2 (66.6%) 3 (100%) 
Non responder 2 (15.4) 11 (84.6%) 13 (100%) 
Total 3 13 16 
 
Table 31. Prevalence of participants who developed OAS among DENV seropositive 
and DENV seronegative participants according to IgG DENV ELISA. 
 Sin Non sin Total 
DENV seropositive 
(by IgG) 
3 (30%) 7 (70%) 10 (100%) 
DENV seronegative 
(by IgG) 
0 (0%) 6 (100%) 6 (100%) 






Table 32. Prevalence of participants who developed OAS among DENV seropositive 
and DENV seronegative participants according to PRNT70. 
 Sin Non sin Total 
DENV seropositive 
(by PRNT70) 
3 (25%) 9 (75%) 11 (100%) 
DENV seronegative 
(by PRNT70) 
0 (0%) 4 (100%) 5 (100%) 
Total 3 13 16 
 
Overall, we are not able to present any conclusive evidence that OAS adversely affects 
JE vaccination. However, OAS does exist after LAJV, a finding not previously 
described.    
Discussion 
Since the LAJV has been introduced, it has been administrated to more than 700 
million children267. The vaccine has been extensively shown to be safe and well 
tolerated by children as young as 8 months as well as by older people 15 years of 
age267. The safety of LAJV among the 17 participants vaccinated was previously 
reported; 6 adverse events were observed in 3 subjects and included fever, headache, 
myalgia, sore throat, dry cough and dizziness158.  
In JE endemic countries a single dose of LAJV SA14-14-2 has high efficacy99,268. 
However, one case control study conducted in China found 80% and 97.5% efficacy 
of 1 and 2 doses, respectively101. Seroconversion following JE vaccination is usually 
analysed by PRNT50, a value equal or above 10 is considered positive, and taken to 
indicate protection. Several studies have looked at seroconversion following LAJV, 
and have showed a range of seroconversion rates from 80-99% 97, 98. In this study a 
lower seroconversion rate was found. As PRNT70 values were used, this may have 
decreased the number of volunteers who seroconverted. In our previous published 
work on this cohort of participants, a seroconversion rate of 62.5% was measured by 
PRNT50158. Another reason for the low seroconversion rate was the population to 
whom LAJV was administered in this study, which consisted of Indian adults with a 
median age of 25 years (range 20-39), whereas the vaccine is usually used in children. 





of 57.69 and 39.74% respectively at week 4 and 8 in adults following JEV vaccination 
with SA14-14-281,102, a very similar rate (62.5%) to that observed in this population 
using the equivalent measure (PRNT50)158. Another study, conducted in Indian adults, 
described an 85.5% seroconversion rate in subjects that were JEV seronegative at 
baseline269. Interestingly, however, a vaccine efficacy of only 43.8% was observed in 
a case control study conducted in Indian children103. 
This study found a low GMT among responders at 4 and 8 weeks after vaccination. In 
a similar age group to this study, Singh et al. also reported low GMT against  JEV in 
Indian volunteers vaccinated with the LAJV (36.50 at week 4 and 31.84 at week 8 
calculated by PRNT50). The antibody response in this study peaked at week 4 and 
declined at week 8, similar to the findings of two other studies 81, 269.  
Dengue cases have gradually increased over recent years in India270. The majority of 
the participants in this study were DENV exposed, as shown by IgG and NAb specific 
to DENV. The higher GMT and prevalence at baseline of antibodies to DENV2 is 
consistent with previous epidemiological data from Karnataka state265 that indicate 
greater circulation of DENV2 than other serotypes. 
Secondary infection with any DENV serotype is an important risk factor for 
developing a more severe form of dengue disease. For this reason, many studies have 
focused on understanding the antibody response during a secondary DENV infection. 
Antibody responses to other flaviviruses during a secondary flavivirus infection have 
been less well studied. Previous work on DENV can be partially translated in 
understanding these data as protein identity among DENV serotypes is around 70% 
whereas protein identity between JEV and any DENV serotype is around 50%. A 
secondary heterologous DENV infection is dominated by a cross-reactive antibody 
response173, 271. The major target of these antibodies is the virion where they bind 
mainly to prM and E proteins. Anti-prM antibodies were shown to be poorly 
neutralising181. Anti-E antibodies have different degrees of neutralisation and cross-
reactivity, depending upon their epitope specificity. The most well characterized, 
poorly neutralising, highly cross-reactive antibodies were demonstrated to bind the FL 
region of the E protein: a highly conserved region among all flaviviruses261, 182. 
Antibodies that bind the E protein FL in secondary DENV infection have some 





high affinity, but they do not neutralise at all262. It is possible that a similar class of 
cross-reactive, but non-neutralising, antibodies were made after LAJV in these 
volunteers, which could neutralise DENV somewhat, but did not neutralise JEV. 
Both the antibody response and the T cell response during secondary heterologous 
DENV infection can exhibit OAS195 202 264. In this study, OAS was observed in the 
NAb response of 3 participants following JE vaccination.   
This is the first study demonstrating this phenomenon with JEV and DENV, viruses 
more distantly related than DENV serotypes.  
The mechanism at the base of the phenomenon of OAS is still unknown. One 
hypothesis suggests that there is competition for B cell receptor antigen binding among 
naïve and memory B cells with the latter outcompeting naïve cells by being present in 
higher number and having a lower activation threshold193. Another hypothesis invokes 
activation of regulatory T (Treg) cells, primed by the original and able to recognise the 
second antigen, which reduce the amount of antigen loaded on antigen presenting cells 
and limit the activation of naïve B cells198. Neutralisation of the anti-inflammatory 
cytokine IL-10 prevented OAS in an animal model, although Treg cells were not found 
to be the source of IL-10200. Previous work, which identified two strategies to block 
OAS, supports both hypotheses: repeated stimulation with the secondary antigen or 
the use of adjuvants to stimulate antigen presenting cells199. 
As the mechanism behind OAS is still unknown, it is difficult to explain why this 
phenomenon was observed only in some volunteers. It can be speculated that increase 
of the phylogenetic distance among viruses may reduce the occurrence of the 
phenomenon, which may depend on the original infecting strain of DENV.  
OAS was first observed in influenza191, where some animal model data suggest a 
biologically relevant effect on protection. In the work of Kim et al., OAS was observed 
in mice vaccinated with different types of influenza vaccines (inactivated, 
deoxyribonucleic acid (DNA) and live attenuated vaccines) and it was responsible for 
reduced efficacy of the vaccine193. In humans, however, the clinical relevance of OAS 
is still a matter of debate. Some studies found no interference by OAS in vaccine 
efficacy or did not observe the phenomenon at all272,194. Decreased vaccine 
seroconversion due to OAS is well described201, 273, but whether this results in lack of 





The data presented here show that although OAS occurs after JE vaccination, it did 
not necessarily hinder the development of anti-JEV NAb. Whether OAS can account 
for the poor immunogenicity of JE vaccine seen in this study, and in other studies in 
India, remains unclear. We only studied a small number of subjects, and a larger study 
may yet reveal a role for OAS in hindering the NAb response to JE vaccine.   
More participants responded to the vaccine by measuring IgM specific to JEV although 
only a modest increase was observed following LAJV. This is in agreement of the 
work of Sohn et al. where only 13% of the children immunized with 1 dose of the 
LAJV produced IgM specific to JEV274. The results presented in this thesis also 
suggested a non-neutralising response mounted by the participants with a serological 
profile of JEV IgM+ JEV PRNT-. Whilst this profile could be explained by an increase 
in cross-reactive non-neutralising antibodies, such as FL antibodies, this response was 
also observed in DENV seronegative participants. Our data regarding JEV specific 
IgG are difficult to interpret. Higher JEV IgG levels were observed in the participants 
who were DENV seropositive. Additionally, one participant who was JEV IgG 
positive became negative following vaccination, questioning the reliability of the 
assay. Furthermore, it is important to note that the assay used was developed to detect 
natural exposure and not vaccine response, as stated by the manufacturer. The most 
likely confounding factor is the cross-reactivity of this assay with DENV antibodies. 
Overall, these data confirmed how difficult it can be to discriminate between anti-JEV 
or anti-DENV antibodies, or more generally among flaviviruses, in countries where 
different flaviviruses co-circulate.  
Measurement of IgG and IgM against DENV by ELISA did not show any increase 
following vaccination despite observing an increase of DENV NAb in some 
participants. This indicated that the ELISAs detected antibodies with different 
specificity than those measured by PRNT70. An explanation for these data could be the 
use of diagnostic ELISA tests (the antigen used is not mentioned) that have probably 
been designed to avoid cross-reactive antibodies, or could employ the secreted NS1 
protein as antigen. 
Another important finding of this study was the higher titre of IgG and NAb against 
DENV in those participants who responded to LAJV. These data are in agreement of 





vaccination (inactivated vaccine) increased the immunogenicity of yellow fever 
vaccine by increasing infectivity, viraemia and the pro-inflammatory response243. The 
role of pre-existing antibodies in flavivirus infection has been investigated in different 
studies. Interesting data came from the first human clinical trial of a dengue vaccine 
where a chimeric DENV was administrated to volunteers in endemic countries (prM 
and E of each dengue serotype with a backbone of the live attenuated yellow fever 
vaccine)234–236. The vaccine, which did not show high efficacy, enhanced DENV 
infection in volunteers who were DENV seronegative at the time of vaccination238,275. 
Several studies have looked at the role of these cross-reactive antibodies among 
flaviviruses of different serogroups in natural infection. Anderson et al. associated pre-
existing NAb to JEV with a higher rate of symptomatic dengue infection upon 
subsequent exposure248. This was not the case for those who had received inactivated 
JE vaccine, suggesting that natural exposure accounted for the phenomenon. More 
recently, many studies have described the interaction of DENV antibodies with ZIKV. 
Although there is strong evidence that cross-reactive antibodies, including anti-FL 
antibodies, promote enhancement of ZIKV in vitro262, their role in vivo is still unclear. 
Studies using non-human primate and human studies have shown no evidence of ADE 
in vivo276,277. Consistent with this are observations that previous DENV is protective, 
and not detrimental, for subsequent ZIKV infection278,279. 
In this project the only protective mechanism studied was direct neutralisation of the 
virus by the Ab response. Direct neutralisation is believed to be the main mechanism 
of protection by antibodies in flavivirus infection, although a role for other 
mechanisms is not excluded. Other antibody mediated anti-viral mechanisms are 
antibody-dependent cellular cytotoxicity (ADCC), complement fixation, and 
opsonisation. Although a previous study demonstrated that ADCC kills DENV 
infected cells in vitro280,  García et al. found ADCC occurring only with serum samples 
collected from severe cases of dengue281. More work is still required to elucidate the 
implications of this phenomenon in the protection from the disease. No work has been 
published to date on ADCC in JE, therefore more experiments looking at this aspect 
of the antibody response are necessary.  
The role of the complement fixation by anti-flavivirus antibodies has been studied 
mainly in WNV and DENV with both protective and pathogenic effects described. In 





presence of WNV specific IgM and complement282. On the contrary, Melhlop et al. 
showed that the complement component C1q in presence of IgG subclasses 1 and 3 
could abolish ADE in vitro and in vivo283.    
The main limitation of this study is the sample size which limits the conclusions that 
can be drawn. In addition, the ELISAs performed in this study were not quantitative 
in nature but qualitative and are intended for diagnostic purposes. Although these 
assays gave helpful information about the serological status of the participants, 
including the non-neutralising component of the response, the IgM and IgG JEV kits 
were not designed to detect a response to JE vaccine. Moreover, the antigen used to 
bind the antibodies is not specified making the data difficult to interpret. ELISA using 
whole JEV and DENV virions as antigen may have helped to have a more complete 
overview of the antibody response and its degree of cross-reactivity.  
Most of the participants had detectable T cell proliferation responses to JEV at 
baseline, whereas NAb at baseline were observed only in one participant158. Although 
DENV cross-reactive T cells may give rise to proliferation responses, T cell 
proliferation responses were observed also in DENV seronegative volunteers. This 
could represent a model of immunity with memory T cells providing protection even 
in the absence of NAb158,284.     
In summary, this study showed low immunogenicity of the LAJV in Indian adults. 
Larger studies, or studies with clinical disease as the end point, are therefore required 
to confirm these observations and define their clinical relevance. Additionally, this 
work describes the phenomenon of OAS occurring among the LAJV and DENV in 
some participants for the first time. However, we were unable to determine any impact 
of OAS on JE vaccination. Finally, this study suggests that pre-existing DENV 















This chapter includes data obtained by other colleagues.  
Figure 40 was produced by others.  
I re-analysed data obtained by other colleagues to generate figures 42-46. 
Figure 48, table 33 and table 36 together with my data include data previously 





















The main marker used to measure response to Japanese encephalitis (JE) vaccines is 
seroconversion by analysing production of neutralising antibody (NAb) against 
Japanese encephalitis virus (JEV). NAb play a crucial role in protection against JEV 
and a titre of 1:10 (PRNT50) is considered protective. The role of T cells in JE is much 
less studied and is not fully understood. Similarly, a knowledge gap exists regarding 
the T cell response to the live attenuated JE vaccine (LAJV). Animal and human 
studies have implied a role for T cells in protection. Both CD4 and CD8 T cells 
together contributed to protection in a mouse model, although CD8 T cells were also 
found to be involved in pathogenesis in the central nervous system (CNS)147 285. Other 
studies have confirmed the importance of T cells in controlling JEV. Jain et al. 
demonstrated the importance of CD8 T cells in reducing mortality by adoptive transfer 
experiments and highlighted the importance of the lytic activity of these cells in 
controlling the viral infection148. Similar findings were observed in another study 
where adoptive transfer (intracerebral) of anti JEV cytotoxic T cells protected adult 
mice from a lethal intracerebral JEV challenge149.  
In human, Turtle et al. described differences of T cell responses among JEV exposed 
healthy individuals (asymptomatic JEV infections) and JE recovered patients. A higher 
frequency of CD8 responses targeting the non-structural proteins were observed in 
healthy JEV exposed donors in comparison to recovered JE patients where CD4 T cells 
responding to the structural proteins dominated the response. The quality of the CD4 
T cell response was also related to the outcome of JE with polyfunctional responses 
being associated with complete recovery157. Furthermore, other studies have 
associated interferon-γ (IFNγ) production with good outcome in JE156,154 again 
indicating that T cells have a role in protection from JE. 
In previous work related to this thesis, our group described the T cell response to 
LAJV. Response to all JEV proteins was detected with both CD4 and CD8 T cells 
responding to JEV peptides. Additionally, cross-reactivity with dengue virus (DENV) 
and West Nile Virus (WNV) peptides was also described for some of these epitopes158.  
In another live attenuated flavivirus vaccine (yellow fever), polyfunctional T cell 
responses, CD4 and CD8, to all proteins were described286 287. The tetravalent dengue 





Health, induced similar patterns of response with polyfunctional CD4 and CD8 T cells 
following administration288 289. Interestingly, differences were found among 
monovalent and tetravalent vaccine administration, with T cell responses focusing on 
more conserved epitopes following vaccination with the tetravalent vaccine290. This 
was also observed in a mouse model transgenic for human leukocyte antigens (HLA) 
lacking the α/β interferon (IFN) receptors where heterologous infection with different 
DENV serotypes skewed the T cell response towards conserved epitopes with an 
impairment to develop serotype specific T cells291.  
The aims of this work were: 
 To expand the work previously conducted on the same cohort of participants and 
to map more T cell epitopes. In so doing, to: 
1. explore whether any aspect of the T cell response to LAJV correlates with the 
existence of OAS in the NAb response. 
2. understand if previous T cell responses to DENV could hinder the development 
of new T cell responses following the administration of the LAJV. 
Initial work on the analysis of the T cell response following LAJV was performed by 
Dr Lance Turtle and co-workers. T cell responses were measured at baseline and week 
1, 2, 4, 8, 16 and 26 following vaccination by IFNγ-ELISpot. One volunteer had a 
detectable T cell response to NS3 (peptide ALRGLPVRY, NS3, 1739-1747) at 
baseline. However, proliferation responses measured using frozen cells were observed 
in 9 out of 13 volunteers tested in both CD4 as well as CD8 T cells before vaccination. 
After vaccination, T cell response was detected by IFNγ-ELISpot in 12 volunteers out 
of 15. Overall, the response peaked at week 2 with a geometric mean spot forming 
cells (SFC) per million peripheral blood mononuclear cell (PBMC) of 77.5 (figure 40) 






Figure 40. T cell response to JEV following LAJV. 
Geometric mean of SFC per 1 million PBMC observed following LAJV with bar 
indicating the 95% confidence interval. PBMC were stimulated with JEV peptide pools 
and T cell response measured by IFNγ-ELISpot. Figure edited from Turtle et al. 158.  
The work described in this chapter involved identification of T cell epitopes in PBMC 
collected after vaccination by use of a peptide library spanning the whole JEV 
proteome. Once a T cell epitope is identified, its cross-reactivity against DENV variant 
peptides was also measured. Finally, the identified T cell responses and their cross-
reactivity with DENV peptides were assessed in PBMC collected before vaccination 
in order to determine if a T cell epitope response was present before vaccination or 
was a de novo response mounted following LAJV administration.   
A diagram of the work performed by me, on stored samples, during the period 2015-






Figure 41. Flow diagram of the T cell experiments performed. 
Results 
Further analysis of the T cell response measured by IFNγ-ELISpot 
NS3 and NS5 have been described as the main immunodominant proteins for T cell 
responses in flaviviruses292. To test the hypothesis that T cell responses to the LAJV 
are mainly directed against NS3 and NS5 proteins, I re-analysed the ELISpot data 
previously obtained by other colleagues stratifying the responses per number of 
volunteers that show a response to a specific protein or per average number of spots 
per million PBMC for each protein. Responses against NS1, E, NS3 and NS5 were the 
most frequent with 10, 9, 9 and 9 participants responding to these proteins respectively 
(figure 42). However, no difference could be observed among the JEV proteins in 
terms of magnitude (average number of spots per protein) of the responses (figure 43). 
These data are in agreement with previous works on other flavivirus vaccines which 






Figure 42. Number of participants responding to peptide pools stimulation by 
IFNγ-ELISpot per protein.  
 
Figure 43. T cell response against each JEV protein following LAJV. 
Average number of spots per response against JEV proteins measured by IFNγ-
ELISpot from all participants with error bars indicating standard deviation. 
To assess the correlation between T cell and antibody response following vaccination, 





who did not (chapter 2, table 18). A comparison of the T cell response among 
responders (n=3) and non responders (n=13) was performed. Interestingly, no 
significant difference was observed indicating that despite not producing NAb specific 
to JEV, most of the participants were able to mount a T cell response (figure 44 and 
table 33). One possibility is that T cell responses in the non responders are due to 
DENV cross-reactive T cells that expanded following vaccination. To test this 
hypothesis, non responders were stratified according to their DENV serological status.  
However, no difference was observed among the non responding DENV seropositive 
(n=9) and seronegative (n=4) individuals, confirming that some participants were able 
to mount a T cell response without producing NAb following LAJV vaccination 
(figure 45). Overall, considering NAb and T cell response only 2 participants out of 
15 (IFNγ-ELISpot was not performed for 010c3k1) did not respond to the LAJV at all 
(table 33). 
 
Figure 44. T cell responses among responders and non responders to LAJV by 
NAb. 
Median of SFC / 1 million PBMC with bar indicating the interquartile range. Response 
was measured by IFNγ-ELISpot against all peptide pools individually in responders 
and non responders. p value measured by Mann-Whitney test is shown for each time 






Figure 45. T cell responses among non responders (by NAb) DENV seropositives 
and seronegatives.  
Median of SFC / 1 million PBMC with bar indicating the interquartile range. Response 
was measured by IFNγ-ELISpot against all peptide pools individually in non 
responders DENV seropositive and seronegative participants. p value measured by 
Mann-Whitney test is shown for each time point.   
Although all participants were vaccinated with the LAJV, some participants showed a 
higher NAb response against DENV in contrast to a NAb response to JEV which was 
lower or null. This observation consisted in the phenomenon of OAS. To test the 
hypothesis that T cell response specific to JEV may be hindered in volunteers with 
OAS, I stratified the participants according to the observation of the phenomenon of 
OAS in the NAb response. Although the sample size was small, no statistical 
difference was found among participants who developed OAS (n=3) and who did not 
(n=9) (DENV seronegative participants were not included in this analysis) indicating 
that OAS observed for antibody response was unrelated to the T cell responses specific 






Figure 46. T cell responses following LAJV administration stratified per OAS. 
Median of SFC / 1 million PBMC with bar indicating the interquartile range. Response 
was measured by IFNγ-ELISpot against all peptide pools individually in participants 
who developed OAS and who did not (DENV seronegatives were excluded). p value 



















Table 33. T cell and NAb response and OAS following LAJV 
Participant  
Response following LAJV 
IFNγ-ELISpot NAb OAS 
005c3k1 Yes Yes Yes 
001c1k1 Yes Yes No 
023c1k1 No Yes No 
015c3k1 Yes No No 
023c3k1 Yes No No 
020c1k1 Yes No No 
008c3k1 No No No 
019c3k1 No No Yes 
007c1k1 Yes No Yes 
017c1k1 Yes No No 
022c3k1 Yes No No 
018c1k1 Yes No No 
012c3k1 Yes No No 
020c3k1 Yes No No 
004c1k1 Yes No No 
010c3k1 NA No No 
 
T cell epitope mapping  
T cell responses in secondary heterologous DENV infection or in secondary flavivirus 
infection are mostly towards cross-reactive epitopes255,293. To test the hypothesis that 
T cell responses against JEV but cross-reactive to DENV were more frequent in DENV 
exposed participants, T cell epitope mapping and cross-reactivity was studied. 
Although ELISpot is able to identify T cell responses, it cannot be used to study cross-
reactive T cell responses among JEV and DENV peptide variants.  
The first step to study cross-reactivity among T cell epitopes is to identify T cell 
responses to JEV. To identify and characterize the T cell responses, short-term T cell 





preferentially performed by using PBMC collected at the time point that showed the 
highest response by ELISpot to the peptide pools.  
The initial strategy used consisted of expansion of a TCL using a pool of peptides. 
Epitope mapping was performed in two steps: firstly, the TCL was stimulated with 
deconvoluted mini-pools (MP) of 6-10 peptides and tested by intracellular cytokine 
staining (ICS), followed by another round of stimulation of the TCL using the peptides 
of the responding MP.  
Figure 46 illustrates an example of the epitope mapping strategy using stored PBMC 
from participant 020c1k1. This participant responded to pool 9 (NS5, 2526-2841) by 
ELISpot (62 SFC/106 PBMC) at week 2. A TCL was expanded against pool 9 from 
PBMC collected at week 2. Following 7 days of expansion, the TCL was stimulated 
with MP of pool 9 and response identified by ICS. A small, but clear response was 
detected in 0.79% of CD3+CD8+ cells stimulated with MP3 (NS5, 2602-2659). In the 
second step to map the epitope, the TCL was stimulated with the peptides that 
constituted MP3 (P371-P377) (table 34): 
Table 34. Peptides composing MP3 of pool 9. 
Peptide Sequence Protein AA position 
371 GKVIDLGCGRGGWSYY NS5 2602-2617 
372 GCGRGGWSYYAATLKKV NS5 2608-2624 
373 SYYAATLKKVQEVRGYTK NS5 2615-2632 
374 KVQEVRGYTKGGAGH NS5 2623-2637 
375 RGYTKGGAGHEEPMLM NS5 2628-2643 
376 GAGHEEPMLMQSYGWNLV NS5 2634-2651 
377 LMQSYGWNLVSLKSGVDV NS5 2642-2659 
 
These data identified the antigenic peptide as P376 (GAGHEEPMLMQSYGWNLV, 
















Figure 47. Epitope mapping strategy.  
TCL expanded from PBMC collected at week 2 from 020c1k1. In the first step the TCL 
was stimulated with MPs of pool 9 for 6 hours and T cell response measured by ICS 
(A and C) (cells gated on lymphocytes/singlets/live/CD3+/CD8+). In the second step, 
the TCL was stimulated with the peptides of MP3 for 6 hours and response measured 
by ICS identifying the responding epitope P376, GAGHEEPMLMQSYGWNLV, NS5, 
2634-2651 (B and D).  
Epitope mapping was initially performed by Dr Lance Turtle who identified 21 T cell 






I expanded this work by growing 22 TCLs from 9 participants as illustrated in table 
35. However, T cell expansion followed by epitope mapping was successfully 
achieved for only 2 volunteers which lead to the identification of a total of 2 epitopes 
both from CD3+CD8+ cells: GAGHEEPMLMQSYGWNLV (NS5, 2634-2651) from 
020c1k1 and NVKDTACLAKAYAQMWLL (NS5, 2634-2651) from 007c1k1 (table 
36).  
TCL expansion was also achieved for another 3 epitopes which were previously 
identified by Dr Lance Turtle all from CD3+CD8+ cells:  ALRGLPVRY (NS3, 1739-
1747) from 001c1k1, TAVLAPTRVVAAEMAEVL (NS3, 1723-1740) from 012c3k1 
and IEGASGATWVDLVLEGDSCLTIM (E, 306-328) from 020c1k1 (table 36)158. 
More cells were available for these volunteers, therefore these TCL expansions were 











Stimulus for expansion Epitope identified 
T cell 
subset 
001c1k1 Week 4 
RVPNYNLFVMDEAHF, NS3, 1779-1793 
DFHFIDDPGVPWKVWVLR, NS2b, 1457-1474 
None NA 
001c1k1 Week 2 ALRGLPVRY, NS3, 1739-1747 ALRGLPVRY, NS3, 1739-1747 CD8 
001c1k1 Week 8 NS3, 1810-2126 None NA 
004c1k1 Week 2 NS5, 2832-3130 None NA 
004c1k1 Week 4 NS5, 2832-3130 None NA 
018c1k1 Week 4 NS3, 1500-1819 None NA 
018c1k1 Week 4 NS3, 1500-1819 None NA 
018c1k1 Week 1 NS3, 1500-1819 None NA 
020c1k1 Week 1 
IEGASGATWVDLVLE, E, 306-320 
GATWVDLVLEGDSCLTIM, E, 311-328 
GATWVDLVL, E, 311-319 CD8 
020c1k1 Week 2 NS3, 1810-2126 None NA 
020c1k1 Week 4 NS3, 1810-2126 None NA 
020c1k1 Week 2 NS5, 2526-2841 NS5, 2602-2659 CD8 






020c3k1 Week 2 E, 538-799 None NA 
023c3k1 Week 4 E, 294-547 None NA 
007c1k1 Week 2 NS5, 3121-3432 NS5, 3247-3296 CD8 
007c1k1 Week 2 NS5, 3121-3432 NVKDTACLAKAYAQMWLL, NS5, 3279-3296 CD8 
007c1k1 Week 4 NS5, 3121-3432 NVKDTACLAKAYAQMWLL, NS5, 3279-3296 CD8 
012c3k1 Week 1 NS2a/b, 1145-1509 None NA 
012c3k1 Week 1 NS5, 3121-3432 None NA 
012c3k1 Week 1 TAVLAPTRVVAAEMAEVL, NS3, 1723-1740 APTRVVAAEM, NS3, 1727-1736 CD8 





As PBMC were stored in the liquid nitrogen for 3-5 years, proliferation capacity of the 
cells could have been compromised making difficult identification of T cell epitopes 
by expansion of TCL. For this reason, an alternative approach, IFNγ-ELISpot directly 
on thawed cells without in vitro expansion, was used to try to map other T cell epitopes. 
Despite resting the PBMC in R10 overnight after having thawed them before 
stimulating them with peptides294, all participants showed high background on 
stimulation with the DMSO control. A spot count at least three times that of the 
negative control was considered as positive response. Despite several attempts, on 
different participants and time points, no T cell epitope could be identified. 
Overall, combining the results obtained by me and other colleagues on this cohort of 
participants, 17 T cell epitopes (CD4 n=9, CD8 n=7, not determined n=1) from a total 
of 6 volunteers were identified. Interestingly, 8 responses were identified from the 
volunteer 019c3k1. Five responses were identified against the prM and NS3, 3 against 





















































005c3k1 No Yes NA NA NA NA No NA 
001c1k1 Yes Yes ALRGLPVRY, NS3, 1739-1747 Yes Yes Yes Yes Yes 
023c1k1 No Yes NA NA NA NA Yes NA 
015c3k1 No No NA NA NA NA Yes NA 
023c3k1 No Yes NA NA NA NA NT NA 
020c1k1 No Yes 
GATWVDLVL, E, 311-319 
 





No Yes No No 
008c3k1 No No NA NA NA NA Yes NA 







NT= not tested 
NA= not applicable
007c1k1 No Yes 
NVKDTACLAKAYAQMWLL, 
NS5, 3279-3296 
Yes Yes Yes No No 
017c1k1 No Yes NA NA NA NA Yes NA 
022c3k1 No Yes NA NA NA NA NT NA 
018c1k1 No Yes NA NA NA NA Yes NA 
012C3k1 No Yes 
APTRVVAAEM, NS3, 
1727-1736 
No Yes Yes Yes Yes 
020c3k1 No Yes NA NA NA NA No NA 
004c1k1 No Yes NA NA NA NA No NA 
010c3k1 No NT NA NA NA NA NT NA 





Individual mapped peptides in the previous work (15 epitopes, n participants=5)







JE virus amino acid
Figure 48. Summary of identified T cell epitopes. 
Location of the epitopes studied in this project (A) and in the previously published work (B). 
Figure edited from Turtle et al.158 
As more cells were available for the participants 020c1k1 and 012c3k1, the minimal epitopes 
corresponding to two peptides previously identified by others from these participants were 
determined. The previously identified peptides were: IEGASGATWVDLVLE (Envelope (E), 
306-320) and GATWVDLVLEGDSCLTIM (E, 311-328) detected from the participant 
020c1k1 and peptide TAVLAPTRVVAAEMAEAL (NS3, 1723-1740) identified from 
012c3k1. Both of these epitopes were detected from CD8 T cells. Fine mapping was performed 
by growing the TCL with the peptide epitope and stimulating it with different truncated variants 
of the peptide and analysing which variant was giving the highest response. Truncated variants 
were designed by Dr Lance Turtle by an epitope binding prediction software (iedb.org) using 
the HLA I molecules identified from these participants. HLA typing was performed by Rotary 
TTK blood bank, Bangalore by polymerase chain reaction.     
A TCL expanded with IEGASGATWVDLVLE and GATWVDLVLEGDSCLTIM from 
PBMC collected from 020c1k1 at week 1 was stimulated with the truncated peptides: 
ATWVDLVL, GATWVDLVL, GASGATWVDL and VLEGDSCLTI. Responses were 
observed only when the first two peptides (1.21% and 1.36% responding cells for 
ATWVDLVL and GATWVDLVL respectively) were used to stimulate the TCL (figure 49). 
The peptide GATWVDLVL was considered to be the minimal epitope as a slightly higher 
response was obtained. Using a similar strategy, a TCL expanded with 
TAVLAPTRVVAAEMAEAL from PBMC collected at week 2 from 012c3k1 identified the 
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Figure 49. Example of identification of T cell minimal epitope. 
TCL expanded with IEGASGATWVDLVLE (E, 306-320) and GATWVDLVLEGDSCLTIM (E, 
311-328) from PBMC collected at week 1 from 020c1k1. The minimal T cell epitope was 
identified by stimulation of the TCL with the peptide variants indicated, followed by 
measurement of the response by ICS. Data are percentage of CD8+ T cells staining for IFNγ 
or TNFα in any combination. 
Cross-reactivity of the T cell epitopes 
As the 4 DENV serotypes co-circulate with JEV in India and majority of the participants were 
shown to be DENV exposed by the presence of NAb (chapter II, table 19), cross-reactivity of 
the T cell epitopes identified was also studied. Expansion of TCLs could be achieved for only 
few epitopes and participants therefore it was not possible to test the hypothesis that cross-
reactive epitopes were more frequent in DENV exposed participants. T cell cross-reactivity 
among flavivirus is known, therefore I tested the hypothesis that the live attenuated JEV 
vaccine would have raised DENV cross-reactive T cell responses. For this work, peptide 
libraries of the E, NS1, NS3 and NS5 proteins of DENV 1, 3 and 4, and a full length library 
for DENV2 were obtained from Biodefense and Emerging Infection resources (National 
Institutes of Health).  
Cross-reactivity was studied by stimulating the short-term TCL expanded with the JEV peptide 
individually with the corresponding peptides of the 4 DENV serotypes and the JEV peptide. 





to the DENV variant peptides divided by the percentage of responding cells to the JEV peptide, 
after background subtraction157. Therefore, a value of 1 indicates a response of equal magnitude 
to JEV, a response >1 indicated a DENV response higher than JEV whereas a response <1 
indicated a not fully cross-reactive response among JEV and DENV.  
I studied the cross-reactivity on a total of 5 epitopes for which a TCL could be expanded. These 
epitopes included the peptides NVKDTACLAKAYAQMWLL, GATWVDLVL, 
GAGHEEPMLMQSYGWNLV, APTRVVAAEM and an epitope previously identified and 
described by Dr Lance Turtle from the participant 001c1k1: ALRGLPVRY (NS3, 1739-
1747)158.   
Additionally, the possibility of degranulation (killing) following peptide stimulation was 
studied by staining for CD107a. Cytotoxicity involves the release of pre-formed lytic granules, 
containing perforin and granzymes, toward the target cell. This process exposes to the cell 
membrane numerous lysosomal-associated membrane glycoproteins (LAMPs) such as 
CD107a. Thus, labelling cells with antibodies specific to CD107a (which is added during the 
assay set up) identify degranulating cells257.   
Finally, each of these epitopes and their cross-reactivity were studied on PBMC collected 
before vaccination. These experiments were crucial to establish which response was already 
present before vaccination and which one was induced by the administration of the LAJV. 
Epitopes identified from 020c1k1 
Two epitopes were identified from the participant 020c1k1: GATWVDLVL (E, 311-319) and 
GAGHEEPMLMQSYGWNLV (NS5, 2634-2651).   
Cross-reactivity for GATWVDLVL was previously studied on PBMC collected after 
vaccination (week 1) by Dr Lance Turtle by using the non-truncated JEV peptide 
(GATWVDLVLEGDSCLTIM) instead of the minimal epitope and high degree of cross-
reactivity was observed for DENV1/3158. I confirmed and expanded previous data for this 
epitope.  TCL expanded at week 1 with GATWVDLVL indicated high degree of cross-
reactivity to DENV1/3 (CRI 0.78) and to a lesser extent with DENV4 (CRI 0.28) (figure 50 
and 51). Response to DENV4 was not previously observed by Dr Lance Turtle for this epitope 
on this participant. This may be due to better expansion promoted by the minimal epitope 
peptide. Moreover, higher level of degranulation was observed when the TCL was stimulated 
with the DENV1/3 (1.28% of CD3+CD8+ cells) and DENV4 (0.35% of CD3+CD8+ cells) in 









































































































Figure 50. Cross-reactivity of GATWVDLVL in 020c1k1. 
TCL expanded with GATWVDLVL (JEV) and SGATWVDVVLEHGGCV (DENV1/3) from 
PBMC collected at week 0 and 1 from 020c1k1. Each TCL was stimulated with all DENV 
serotype variants and JEV peptide. Data shown are percentages of CD3+CD8+ T cells stained 
for IFNγ or TNFα in any combination (A) and CD107a (B). Reciprocal NAb titre at baseline 

























Figure 51. Cross-reactivity index of GATWVDLVL in 020c1k1. 
TCL expanded with GATWVDLVL (JEV) from PBMC collected at week 0 and 1 from 020c1k1 
was stimulated with JEV and DENV peptide variants and percentage of responding cells 
measured by ICS. CRI was measured as ratio between the percentage of responding cells to 
DENV variants and the JEV peptide.  
Interestingly, when a TCL was expanded at week 1 with DENV1/3 variant, response (0.91% 
of responding cells) and degranulation (0.36% of CD3+CD8+ cells) was detected only against 
the JEV peptide  (figure 50), possibly reflecting the increased efficiency of the ICS assay using 
the minimal peptide.  
As this response was cross-reactive and this participant had NAb against DENV1, 2 and 3 at 
baseline, TCLs were expanded with the JEV and DENV1/3 peptides from PBMC collected 
before vaccination to understand if this response was present before vaccination or it was a de 
novo response raised following LAJV administration. Both TCLs showed an expansion 
indicating that this response was elicited following a previous flavivirus infection. Responses 
to DENV1/3, 2 and JEV were respectively of 2.34% (CRI of 0.35), 0.92% (CRI of 0.14) and 
6.64% of responding cells when the TCL was expanded with JEV peptide. Similarly, responses 
to DENV1/3, 2 and JEV were observed when the TCL was expanded with DENV1/3 peptide 
with respectively 1.17%, 0.40%, and 1.38% responding cells. Overall, whereas DENV2 was 
showing a similar level of CRI before and after vaccination, the CRI increased by 2.22-fold 





responding cell populations expanded equally. Finally, a cross-reactive response to DENV4 
was not detected before vaccination but was observed after vaccination. A possibility to explain 
this is that de novo T cells specific to JEV and cross-reactive to DENV4 may have raised 
following vaccination. TCL expanded with JEV at week 0 showed higher degranulation after 
stimulation with JEV (9.6% of CD3+CD8+ cells) followed by DENV1/3 (7.8% of CD3+CD8+ 
cells) and DENV2 (5.4% of CD3+CD8+ cells) peptides. A similar pattern was observed when 
a TCL was expanded on the same time point with DENV1/3 peptide. Higher percentage of 
degranulation was observed when the TCL was stimulated with the JEV peptide (1.26% of 
CD3+CD8+ cells) in comparison to DENV1/3 and 2 which showed a percentage of 
degranulation of CD3+CD8+ cells of 0.71% and 0.56% respectively (figure 50).  
Conversely to GATWVDLVL (E, 311-319), GAGHEEPMLMQSYGWNLV (NS5, 2634-
2651) epitope did not cross-react with any DENV serotype and could not be expanded before 
vaccination indicating that this was an epitope raised following vaccination with LAJV.  
Taking together these results demonstrated that previous DENV exposure does not hinder the 
development of new T cell responses with cytotoxic function.  
Epitope identified from 007c1k1 
The peptide NVKDTACLAKAYAQMWLL was identified from 007c1k1. TCL expanded with 
JEV at week 2 demonstrated that this epitope cross-reacted with all DENV variants although 
the higher degree of cross-reactivity was observed against DENV1/2 (which were sharing the 
same AA sequence for this epitope) and DENV4. The percentage of responding cells detected 
for DENV1/2, 3, 4 and JEV were respectively of 0.76% (CRI of 0.62), 0.48% (CRI of 0.39), 
0.71% (CRI of 0.58) and 1.22% (figure 52 and 53). Interestingly, response to this epitope was 
detected before vaccination indicating that it was not vaccine induced. As this participant was 
DENV seropositive and JEV seronegative at baseline it is likely that the response to this epitope 
was raised initially due to a DENV infection. No cross-reactive response against DENV3 and 
4 were detected on a TCL expanded with JEV peptide at baseline whereas 0.35% (CRI of 0.69) 
and 0.51% of responding cells were detected for DENV1/2 and JEV respectively (figure 52 
and 53). A TCL expanded using the DENV1/2 variant from PBMC collected before 
vaccination confirmed the high degree of cross-reactivity among DENV1/2 (1.4% responding 
cells) and the JEV variant (1.35% responding cells). In addition, a small cross-reactive response 
was also detected when the TCL was stimulated with DENV4 peptide variant (0.32% 






























Figure 52. Cross-reactivity of NVKDTACLAKAYAQMWLL in 007c1k1. 
TCL expanded with NVKDTACLAKAYAQMWLL (JEV) from PBMC collected at week 0 and 2 
and with WSLRETACLGKSYAQMW (DENV1/2) from PBMC collected at week 0 from 
007c1k1. Each TCL was stimulated with JEV and all DENV serotype variant peptides. Data 
are percentage of CD3+CD8+ T cells stained for IFNγ or TNFα in any combination (A) and 
CD107a (B). Reciprocal NAb titre at baseline measured by PRNT against all DENV serotypes 








Figure 53. Cross-reactivity index of NVKDTACLAKAYAQMWLL in 007c1k1. 
 TCL expanded with NVKDTACLAKAYAQMWLL (JEV) from PBMC collected at week 0 and 
2 from 007c1k1 were stimulated with JEV and DENV peptide variants and percentage of 
responding cells measured by ICS. CRI was measured as ratio between the percentage of 
responding cells to DENV variants and the JEV peptide.  
Analysis of degranulation by staining for CD107a indicated higher levels of degranulation 
when the TCL expanded with JEV peptide before vaccination was stimulated with JEV peptide 
(0.42% of CD3+CD8+CD107a+ cells) in comparison to the DENV variants which showed 
degranulation (0.18% of CD3+CD8+CD107a+ cells) only when stimulated with DENV1/2 
peptide. When a TCL was expanded with DENV1/2 before vaccination degranulation was 
observed mainly when stimulated with DENV1/2 and JEV (0.95% and 0.57% respectively of 
CD3+CD8+CD107a+ cells) confirming the cytokines results (figure 52).  
Overall, following vaccination a broadening of cross-reactivity was observed with a cross-
reactive response detected also for both DENV3 and 4 which was not observed at baseline, 
indicating that it is likely the response was either a mixture of newly primed cells and memory 
cells, or memory cells that were too infrequent to be expanded from the baseline samples.  
Epitopes identified from 001c1k1 
In participant 001c1k1, a response to the epitope ALRGLPVRY (NS3, 1739-1747) was 
previously described by Dr Lance Turtle. TCLs were expanded before (with JEV wild type 
(WT) and DENV2/4 peptide variants) and after (week 16) (with JEV WT, JEV vaccine and 





showed high degree of cross-reactivity among JEV WT and DENV2/4 peptides. On contrary, 
the vaccine variant was less efficient in expanding the TCL and showed less cross-reactivity 
with the other peptides although the response was similar when analysed by including the 
cytokine MIP-1β158. I repeated these experiments including the DENV1 and 3 peptide variants 
to confirm previous data from this volunteer. A cross-reactive T cell response with all DENV 
serotypes (DENV1, ALKGMPIRY; DENV2/4, ALRGLPIRY; DENV3, AMKGLPIRY) and 
the vaccine (VLRGLPVRY) variants was observed from a TCL expanded with ALRGLPVRY 
(JEV WT) at week 2. Although, the epitope was cross-reacting with all DENV serotypes, CRI 
was lower for DENV1 (0.18), DENV2/4 (0.41) and the vaccine variant (0.45) in contrast to 
DENV3 (0.84) (figure 55). When a TCL was expanded with the DENV2/4 variant at the same 
time point, similar levels of responses were observed among the DENV2/4 (15.77% 
CD3+CD8+ responding cells), DENV3 (15.16% CD3+CD8+ responding cells) and the JEV WT 
peptide (12.77% CD3+CD8+ responding cells) whereas DENV1 (4.35% CD3+CD8+ 
responding cells) and the vaccine (8.53% CD3+CD8+ responding cells) responses were smaller 
(figure 54). The response to this epitope was present before vaccination and TCLs to JEV WT, 
JEV vaccine, DENV2/4 and 3 were expanded. Cross-reactive responses could be observed for 
all TCLs and with any peptide to similar level except for responses to DENV1 for any TCL, to 
DENV3 for the TCL that was expanded with the DENV2/4 variant and to the vaccine variant 
on the TCL expanded with DENV3 which were showing a lower percentage of responding 
cells (figure 54). Furthermore, JEV WT and DENV2/4 peptides were more efficient in 
expanding the TCL in comparison to the vaccine and DENV3 variants. Detection of anti-
DENV NAb at baseline indicated that this volunteer had been previously infected with DENV, 
possibly DENV 2, which was showing a higher NAb titre. Overall, analysis of the CRI showed 
a decrease in the level of cross-reactivity for all peptide variants following LAJV 
administration. As previously observed for other participants, JEV vaccination may have 
expanded memory as well as newly primed T cells. 
Degranulation was observed for all the peptides and for all TCL expanded before and after 
vaccination. Before vaccination, degranulation (cytotoxic) responses were similar across all 
TCLs and peptides tested (figure 54) except for responses to vaccine and DENV1 on the TCL 
expanded with the vaccine peptide. After vaccination, conversely to what observed from the 
cytokine responses, percentage of CD3+CD8+CD107a+ was similar across all peptides for both 





Overall, the data obtained by me confirmed what previously observed by our group for this 
participant with the vaccine variant being less efficient in stimulating T cells when response 
was measured by production of IFNγ and/or TNFα. However, when response was measured by 
another marker (MIP-1β or CD107a), the vaccine peptide showed similar level of responses 



































































































































Figure 54. Cross-reactivity of ALRGLPVRY in 001c1k1. 
TCL expanded with JEV WT (ALRGLPVRY) and DENV1, 2/4, 3 and vaccine variant from 
PBMC collected at week 0 and with JEV WT and DENV2/4 peptides from PBMC collected at 
week 2 from 001c1k1. Each TCL was stimulated with all DENV serotype variant and JEV (WT 
and vaccine) peptides. Data are presented as percentage of CD3+CD8+ T cells stained for 
IFNγ or TNFα in any combination (A) and CD107a (B). Reciprocal NAb titre at baseline 







Figure 55. Cross-reactivity index of ALRGLPVRY in 001c1k1. 
TCL expanded with JEV WT (ALRGLPVRY) at week 0 and 2 from 001c1k1. Each TCL was 
stimulated with all DENV serotype variant and JEV (WT and vaccine) peptides. CRI was 
measured as ratio between the percentage of responding cells to DENV variant and the JEV 
peptide.  
Epitopes identified from 012c3k1 
The epitope APTRVVAAEM was identified in 012c3k1 after vaccination. As more cells were 
available from this participant, a TCL expanded with this peptide from PBMC collected at 
week 2 was used to study cross-reactivity and identify the minimal epitope for DENV1. 
Truncated peptide variants were designed by an epitope binding prediction software (iedb.org) 
by Dr Lance Turtle using the HLA I molecules identified from this participant (Rotary TTK 
blood bank, Bangalore). DENV2, 3 and 4 were sharing the same AA sequence of JEV for this 
epitope. Responses to DENV1 variant peptides showed high degree of cross-reactivity. In 
addition, these data demonstrated the last AA of the epitope (methionine) was critical for the 
T cell response whereas the highest response was observed with LAPTRVVASEM. 
Interestingly, although, this participant was showing NAb to all DENV serotypes at baseline, 
a T cell response to APTRVVAAEM could not be detected before vaccination indicating that 
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Figure 56. Cross-reactivity of APTRVVAAEM in 012c3k1. 
TCL expanded with APTRVVAAEM (JEV/DENV2/3/4) from PBMC collected at week 2 from 
012c3k1. Each TCL was stimulated with truncated DENV1 peptide variants and 
JEV/DENV2/3/4 peptide. Data are percentage of CD8+ T cells stained for IFNγ or TNFα in 
any combination (A). Reciprocal NAb titre at baseline measured by PRNT against all DENV 
serotypes and JEV are also shown (B). 
Summary of cross-reactivity of T cell responses  
Overall, from the 13 epitopes from which cross-reactivity against DENV was tested (I tested 5 
epitopes: I confirmed data for 2 epitopes previously analysed by Dr Lance Turtle and I analysed 
3 epitopes which were not tested previously), 5 epitopes were cross-reactive against DENV. In 
particular, 4 epitopes cross-reacted against the 4 DENV serotypes, whereas 1 cross-reacted 
against DENV 4 only. Finally, 2 cross-reactive epitopes were observed from NS3 and 1 for E, 
NS1 and NS5.  
As a limited number of epitopes were identified, meaningful group analysis could not be 





cell responses. Both cross-reactive and non cross-reactive CD8 responses showed lytic function 
by staining for the degranulation marker CD107a. Furthermore, previous cross-reactive T cell 
response do not prevent generation of de novo T cell responses. In some cases broadening of 
cross-reactive responses which were present before vaccination was observed following LAJV 
administration indicating that the response was likely a mixture of newly primed and memory 
cells.  
To test the hypothesis that higher NAb response to a specific serotype was related to higher 
cross-reactive T cell response to the same serotype following LAJV vaccination, NAb titre fold 
change at week 4 was plotted against the CRI fold change for each DENV serotype. In 
agreement with the ELISpot data, no significant correlation was identified among these values 
indicating no significant correlation among the antibody and T cell responses (Spearman’s 
correlation, R=-01891, p=0.46) (figure 57). These data indicated that NAb response to a 

















Figure 57. Correlation between the DENV NAb and CRI.  
Correlation between the NAb (at week 4) and CRI fold change for each DENV serotype 
following LAJV. 
Discussion 
This work confirmed and expanded the work previously published by our group158. ELISpot 
data, which were previously published, were analysed stratifying them according to NAb 





before vaccination were crucial as this work was carried out in a country endemic for JEV and 
DENV. This time point enabled the differentiation of de novo T cell responses raised to LAJV 
from anamnestic responses primed by a previous flavivirus infection.  
T cell responses were identified against all proteins with E, NS1, NS3 and NS5 being the most 
frequent. This is in agreement with T cell responses found after vaccination with other 
flavivirus live attenuated vaccines such as the yellow fever and the tetravalent dengue 
vaccine287,288,289.  
Despite proliferative responses being detected before vaccination in some participants, IFNγ 
was not detected at the same time point by ELISpot. Similar findings were observed in patients 
sampled 6 months after recovery from JE156 or in PBMC infected with DENV2 under ADE 
condition where IFNγ was blunted, contrary to proliferation and IL-10 production, which were 
preserved295. An explanation could be a difference in the incubation period (8 days vs overnight 
for proliferation and ELISpot assay respectively) or the type of the response as cells may have 
responded by producing another cytokine other than IFNγ. Finally, another possibility is the 
presence of central memory T cells at baseline which have high proliferating profile with 
production of mainly IL-2 before differentiating into effector memory and producing IFNγ295.  
Another interesting finding observed in some participants was the T cell responses in 
participants who did not mount a NAb response. This may represent an immune profile where 
protection is mediated by memory T cells213,254,284,296. This was previously shown with adoptive 
transfer and challenge studies in animal model of flavivirus infection213,254,296. 
No difference could be observed among T cell responses in participants who developed OAS 
in antibody response and who did not, indicating that OAS in antibody response and 
development of new T cell responses occur independently of each other. OAS at T cell level 
was observed during secondary heterologous infection with DENV with many DENV-specific 
T cells  showing low affinity for the infecting virus leading to the speculation that OAS may 
delay viral clearance202. In dengue, OAS has been proposed as a mechanism to explained higher 
severity in a secondary heterologous infection208 however some evidence indicated that OAS 
is more a general phenomenon that occurs in DENV infection independent of the severity of 
the disease209,210. Evidence of OAS at T cell level impairing the development of new CD8 T 
cell responses and promoting higher pathogenesis was found in a lymphocytic 





Use of a peptide library coupled with flow cytometry allowed mapping and characterisation of 
epitopes for some of these T cell responses. Despite several attempts, I was able to achieve T 
cell expansion only for four participants. In the previous work of Dr Turtle, a good correlation 
was observed among ex vivo cross-reactive responses and expanded in vitro short-term TCL157. 
Therefore, analysis of T cell cross-reactivity in this work was performed on short-term TCL, 
which allowed the use of fewer cells. T cell cross-reactivity was observed by both cytokine 
production and degranulation (CD107a staining). 
Initial work performed by Dr Lance Turtle on this cohort of volunteers identified both CD4 
and CD8 responses. The work performed for this project, however, identified only CD8 T cell 
epitopes. A possible explanation could be the long-term storage of up to 5 years in the liquid 
nitrogen of the PBMC which may have affected the proliferative ability of T cells. Similar 
results were obtained by Owen et al. showing a decrease of CD4 T cell responses in long term 
cryopreserved samples297.  
I was able to expand TCL for a total of 5 epitopes from CD8 T cells and four of them showed 
different degrees of cross-reactivity with the 4 DENV serotype variants. Additionally, two of 
these epitopes (GAGHEEPMLMQSYGWNLV (NS5, 2634-2651) and APTRVVAAEM (NS3, 
1727-1736)) developed after administration of the LAJV whereas the rest of them were present 
before vaccination (ALRGLPVRY (NS3, 1739-1747), GATWVDLVL (E, 311-319), 
NVKDTACLAKAYAQMWLL (NS5, 3279-3296)).  
The response to the APTRVVAAEM peptide identified here was not present before 
vaccination and it was highly cross-reactive with all DENV variants. Considering the fact that 
this participant was DENV seropositive at baseline and that the epitope was cross-reactive, the 
possibility that the epitope was present before vaccination but failed to expand cannot be fully 
excluded. This epitope has been previously identified in healthy JE exposed individuals157 and 
DENV infected people. Additionally this antigenic region was described to bind both HLA 
class I and II molecules292,298. In this project, APTRVVAAEM peptide was found to stimulate 
CD8+ T cells. Although no experiments were carried out to understand the HLA restriction of 
this epitope, previous work identified this epitope as restricted to HLA-B*07:02299, an allele 
carried by participant 012c3k1. Restriction mapping experiments involve the use of a library 
of antigen presenting cells (APC) with known HLA alleles to be used to stimulate the T cells. 
At least one HLA molecule should be shared among the APC and the T cells. The identification 





among the T cells and the APC which were able to promote the response. Although HLA alleles 
were determined158, the lack of an APC library and cell availability did not allow the 
determination of HLA restriction.   
The epitope NVKDTACLAKAYAQMWLL was also cross-reactive and it was also identified 
before vaccination. A similar epitope was identified in Zika virus as well as DENV infected 
individuals290,296 indicating the possibility that this response may have been raised as a result 
of a previous DENV infection, suggested by the presence of NAb specific to DENV1, 2 and 4 
at baseline.  
Participant 020C1K1 showed T cell responses to E (294-547) and NS5 (2526-2841) following 
JE vaccination. These epitopes were identified as GATWVDLVL and 
GAGHEEPMLMQSYGWNLV for E and NS5 respectively. Interestingly, the response to 
GATWVDLVL was cross-reactive with DENV1/3 and 2 and was present before vaccination; 
whereas the response to GAGHEEPMLMQSYGWNLV not only was not cross-reactive but 
was not detected at baseline. This indicated that the presence of pre-existing responses (albeit 
low level) from previous flavivirus infection did not inhibit de novo responses specific to the 
JE vaccine. Because SA14-14-2 is replication competent, this can be inferred to mean that 
previous responses also do not inhibit new responses to a newly infecting virus. 
The epitope GAGHEEPMLMQSYGWNLV was also similar to a previously identified CD8 T 
cell responses to JEV; however cross-reactivity against DENV was not tested157. 
The response to GATWVDLVL peptide was also described in a previous work in a cohort of 
patients with WNV infection300. 
The ALRGLPVRY peptide was initially identified by Dr Turtle on 001c1k1 and cross-reactive 
responses to DENV and JE vaccine peptides were observed. Interestingly, the response against 
the vaccine variant was less efficient, likely indicating priming with a different virus. Indeed, 
the response was present before vaccination possibly raised following a DENV2 exposure as 
the subject was showing the highest NAb titre against this serotype. My experiment on this 
epitope confirmed the cross-reactive nature of this epitope also against DENV1 and 3 and the 
less efficiency cross-reactive response of the vaccine variant. This epitope was also previously 
characterized by Zivny and colleagues301. They described a highly cross-reactive response 
measured by lysis of peptide pulsed APC among DENV2 and DENV3 variants. This is in 
agreement with the findings described here, although the priming virus was different in our 





T cell cross-reactivity among different flaviviruses has been previously studied. Recently, 
strongly cross-reactive T cell responses were found in healthy JEV exposed volunteers but not 
in JE patients157. With the recent Zika outbreak, cross-reactivity among Zika and DENV has 
been an important topic. T cell epitopes raised following DENV infection or a tetravalent 
dengue vaccine were found to cross-react with Zika variants255. 
Although cross-reactive T cells have been described, their role in protection is not fully 
understood. Initial reports described a skewed T cell response upon stimulation with cross-
reactive peptides with an imbalance in TNFα production206. Recently however, more evidence 
suggests a possible protective role for cross-reactive T cells157. Moreover, it was observed that 
T cells primed by DENV2 infection were involved in viral clearance and protection of mice 
from Zika virus challenge254. 
In summary, T cell responses were observed following LAJV in participants who developed a 
NAb response and in those who did not. Together with de novo responses (cross-reactive and 
non cross-reactive), boosted cross-reactive memory responses were also observed indicating 
that previous flavivirus infection did not inhibit new T cell priming.  
A limitation of the project was the small sample size and the limited number of cells available 
for some participants. Finally, the peptide libraries of the 5 viruses used did not have fully 
matching peptides, therefore differences of responses among each virus variant may be due to 
variation in epitope location within the library peptide. HLA restriction and fine mapping 
experiments using tetramers would have helped to understand if OAS at T cell level occurs 
following LAJV in DENV exposed individuals. However, HLA restriction mapping would 
have required to build a panel of lymphoblastoid cell lines which was not possible to achieve 











The present study aimed to examine the antibody and T cell response to the live attenuated 
Japanese encephalitis vaccine (LAJV) in healthy adult flavivirus exposed individuals. The 
study was conducted in India, a country where both Japanese encephalitis virus (JEV) and 
dengue virus (DENV), two flaviviruses, circulate. Samples collected before vaccination were 
crucial for having a clear understanding of the response to the vaccine as most of the vaccinees 
were DENV seropositive at baseline.  
The data obtained in this study are consistent with the low immunogenicity of LAJV in adults 
in India already published in other studies. Using a stringent measure of the PRNT70 value to 
analyse the NAb response to the LAJV, only three out of 16 (18.75%) of the volunteers 
responded. Additionally, the volunteers who responded to the vaccine showed low NAb titres 
specific to JEV which peaked at 4 weeks and started to wane by week 8 following vaccination.  
This study described for the first time the phenomenon of original antigenic sin (OAS) among 
flaviviruses of different serogroups. OAS was observed following LAJV in a total of 3 
volunteers who showed an increase of the NAb titre to DENV rather than to JEV. Among the 
DENV seropositive individuals, OAS was observed in approximately 30% of vaccinees. OAS 
was observed among responders and non-responders, and I was not able to determine a 
relationship between OAS and decreased immunogenicity of the vaccine in the population 
studied, due to the small numbers involved in this study. On contrary, data suggested that 
previous DENV exposure increases immunogenicity of the LAJV. 
Previous work published by our group showed that the LAJV was able to induce T cell 
responses against all JEV proteins which peaked at 2 weeks following vaccination. 
Interestingly, T cell responses specific to JEV were detected following vaccination even in 
volunteers without NAb response. In this project I demonstrated that the vaccine was able to 
induce de novo DENV cross-reactive as well as JEV specific T cell responses. Finally, previous 
cross-reactive DENV responses did not inhibit de novo T cell responses.  
Although it was not possible to show that OAS accounts for the low immunogenicity of the 
vaccine, this phenomenon remains a plausible explanation which needs further investigation. 
Such studies could also confirm whether previous DENV infection may enhance the 
immunogenicity of the vaccine in some people. It remains possible that previous DENV 





Understanding the reasons for this, and whether this translates into differences in clinical 
protection, are crucial outstanding questions. 
To have a better understanding of the antibody response, serum samples collected before and 
after vaccination could be analysed by ELISA using whole virion and NS1 protein of JEV and 
DENV1-4 as antigen. This assay could reveal more subjects responding to the vaccine by 
producing non-neutralising antibodies and the full degree of cross-reactivity induced by the 
vaccine. Another aspect of the antibody response not addressed here but that merits further 
investigation is the phenomenon of antibody dependent enhancement (ADE). Serial dilutions 
of any serum sample containing antibody against DENV shows ADE in vitro. As antibody 
titres specific for DENV change following LAJV administration, it would be interesting to 
determine if ADE occurs at different dilutions before and after vaccination, and the balance of 
neutralising versus enhancing antibody at different time points. Future work could also aim to 
definitively show the phenomenon of OAS for T cells following vaccination with LAJV in 
volunteers with previous DENV exposure. This could be achieved by first identifying minimal 
HLA restricted T cell epitopes of DENV in DENV exposed, JEV seronegative subjects. In 
order to show OAS, it would be necessary to identify epitopes that vary between DENV and 
JEV, and are partially cross-reactive before JE vaccination. The specificity of the T cells would 
then be studied before and after vaccination by using differentially labelled HLA class I-peptide 
tetramers loaded with the DENV peptide and the corresponding JEV variant. OAS would be 
demonstrated if the T cell response to the DENV epitope increased in magnitude more than the 
JEV peptide after JE vaccination, or if the antigen specific T cell population appearing after 
vaccination bound the original DENV serotype better than the JEV epitope. Finally, it will be 
interesting to determine if administration of a second dose of the LAJV would improve the 
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